<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Health Serv Res</journal-id><journal-title>BMC Health Services Research</journal-title><issn pub-type="epub">1472-6963</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17324283</article-id><article-id pub-id-type="pmc">1810248</article-id><article-id pub-id-type="publisher-id">1472-6963-7-28</article-id><article-id pub-id-type="doi">10.1186/1472-6963-7-28</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Cost-effectiveness of collaborative care for chronically ill patients with comorbid depressive disorder in the general hospital setting, a randomised controlled trial</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Horn</surname><given-names>Eva K</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I4">4</xref><email>EHorn@trimbos.nl</email></contrib><contrib id="A2" contrib-type="author"><name><surname>van Benthem</surname><given-names>Tjeerd B</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>T.B.vanBenthem@olvg.nl</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Hakkaart-van Roijen</surname><given-names>Leona</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>Hakkaart@bmg.eur.nl</email></contrib><contrib id="A4" contrib-type="author"><name><surname>van Marwijk</surname><given-names>Harm WJ</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>HWJ.VanMarwijk@vumc.nl</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Beekman</surname><given-names>Aartjan TF</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I4">4</xref><xref ref-type="aff" rid="I5">5</xref><email>AartjanB@ggzba.nl</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Rutten</surname><given-names>Frans F</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>F.Rutten@erasmusmc.nl</email></contrib><contrib id="A7" contrib-type="author"><name><surname>van der Feltz-Cornelis</surname><given-names>Christina M</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I4">4</xref><xref ref-type="aff" rid="I5">5</xref><email>CFeltz@trimbos.nl</email></contrib></contrib-group><aff id="I1"><label>1</label>Netherlands Institute for Mental Health and Addiction (Trimbos-institute), Utrecht, The Netherlands</aff><aff id="I2"><label>2</label>Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands</aff><aff id="I3"><label>3</label>Institute of Medical Technology Assessment, Erasmus Medical Centre, Rotterdam, The Netherlands</aff><aff id="I4"><label>4</label>Free University Institute for Extramural Research, Amsterdam, The Netherlands</aff><aff id="I5"><label>5</label>Department of Psychiatric Epidemiology and Department of Psychiatry, Free University, Amsterdam, The Netherlands</aff><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>26</day><month>2</month><year>2007</year></pub-date><volume>7</volume><fpage>28</fpage><lpage>28</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1472-6963/7/28"></ext-link><history><date date-type="received"><day>25</day><month>1</month><year>2007</year></date><date date-type="accepted"><day>26</day><month>2</month><year>2007</year></date></history><permissions><copyright-statement>Copyright Â© 2007 Horn et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>Horn et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"></ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title><offsets xml_i="4400" xml_f="4410" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="4421" xml_f="5082" txt_i="22" txt_f="683">Depressive disorder is one of the most common disorders, and is highly prevalent in chronically ill patients. The presence of comorbid depression has a negative influence on quality of life, health care costs, self-care, morbidity, and mortality. Early diagnosis and well-organized treatment of depression has a positive influence on these aspects. Earlier research in the USA has reported good results with regard to the treatment of depression with a collaborative care approach and an antidepressant algorithm. In the UK 'Problem Solving Treatment' has proved to be feasible. However, in the general hospital setting this approach has not yet been evaluated.</offsets></p></sec><sec><title><offsets xml_i="5104" xml_f="5118" txt_i="685" txt_f="699">Methods/Design</offsets></title><p><offsets xml_i="5129" xml_f="6343" txt_i="700" txt_f="1914">CC: DIM (Collaborative Care: Depression Initiative in the Medical setting) is a two-armed randomised controlled trial with randomisation at patient level. The aim of the trial is to evaluate the treatment of depressive disorder in general hospitals in the Netherlands based on a collaborative care framework, including contracting, 'Problem Solving Treatment', antidepressant algorithm, and manual-guided self-help. 126 outpatients with diabetes mellitus, chronic obstructive pulmonary disease, or cardiovascular diseases will be randomised to either the intervention group or the control group. Patients will be included if they have been diagnosed with moderate to severe depression, based on the DSM-IV criteria in a two-step screening method. The intervention group will receive treatment based on the collaborative care approach; the control group will receive 'care as usual'. Baseline and follow-up measurements (after 3, 6, 9, and 12 months) will be performed by means of questionnaires. The primary outcome measure is severity of depressive symptoms, as measured with the PHQ-9. The secondary outcome measure is the cost-effectiveness of these treatments according to the TiC-P, the EuroQol and the SF-36.</offsets></p></sec><sec><title><offsets xml_i="6365" xml_f="6375" txt_i="1916" txt_f="1926">Discussion</offsets></title><p><offsets xml_i="6386" xml_f="6877" txt_i="1927" txt_f="2418">Earlier research has indicated that depressive disorder is a chronic, mostly recurrent illness, which tends to cluster with physical comorbidity. Even though the treatment of depressive disorder based on the guidelines for depression is proven effective, these guidelines are often insufficiently adhered to. Collaborative care and 'Problem Solving Treatment' will be specifically tailored to patients with depressive disorders and evaluated in a general hospital setting in the Netherlands.</offsets></p></sec></abstract></article-meta></front><body><sec><title><offsets xml_i="6939" xml_f="6949" txt_i="2427" txt_f="2437">Background</offsets></title><p><offsets xml_i="6960" xml_f="7134" txt_i="2438" txt_f="2612">Approximately 15% of the Dutch population will experience a major depressive disorder (MDD) at least once in their lifetime, and 6% have experienced an MDD in the past year [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="7165" xml_f="7166" txt_i="2612" txt_f="2613">1</offsets></xref><offsets xml_i="7173" xml_f="7325" txt_i="2613" txt_f="2765">]. Murray and Lopez (Global Burden of Disease Study) stated that MDD will even become the second major cause of disability-adjusted life years in 2020 [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="7356" xml_f="7357" txt_i="2765" txt_f="2766">2</offsets></xref><offsets xml_i="7364" xml_f="7482" txt_i="2766" txt_f="2884">]. Among chronically ill patients in general hospitals, the prevalence of depression varies, ranging from 13% to 50% [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="7513" xml_f="7514" txt_i="2884" txt_f="2885">3</offsets></xref><offsets xml_i="7521" xml_f="7522" txt_i="2885" txt_f="2886">-</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="7553" xml_f="7554" txt_i="2886" txt_f="2887">8</offsets></xref><offsets xml_i="7561" xml_f="7793" txt_i="2887" txt_f="3119">]. Half of all patients with chronic obstructive pulmonary disease (COPD) seem to experience clinically significant symptoms of depression and/or anxiety, and yet, comorbid MDD is frequently not identified or appropriately treated [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="7824" xml_f="7825" txt_i="3119" txt_f="3120">3</offsets></xref><offsets xml_i="7832" xml_f="7833" txt_i="3120" txt_f="3121">,</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="7864" xml_f="7865" txt_i="3121" txt_f="3122">5</offsets></xref><offsets xml_i="7872" xml_f="8129" txt_i="3122" txt_f="3379">] MDD can impair the ability to seek and adhere to treatment for other medical illnesses, which can be hazardous because MDD frequently occurs in combination with a variety of other physical illnesses, including heart disease, stroke, cancer, and diabetes [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="8160" xml_f="8161" txt_i="3379" txt_f="3380">9</offsets></xref><offsets xml_i="8168" xml_f="8170" txt_i="3380" txt_f="3382">].</offsets></p><p><offsets xml_i="8177" xml_f="8511" txt_i="3383" txt_f="3717">Strong associations have been found between physical illness and MDD. The presence of a comorbid depressive disorder has a strong influence on quality of life, self-care, adherence to medication regimens and general functioning. It raises morbidity, mortality and health care costs if combined with various chronic physical diseases [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="8543" xml_f="8545" txt_i="3717" txt_f="3719">10</offsets></xref><offsets xml_i="8552" xml_f="8553" txt_i="3719" txt_f="3720">-</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="8585" xml_f="8587" txt_i="3720" txt_f="3722">16</offsets></xref><offsets xml_i="8594" xml_f="8838" txt_i="3722" txt_f="3966">]. A meta-analysis of twelve studies showed that the presence of MDD even triples the likelihood of non-adherence to medical treatment recommendations and also increases the risk of subsequent physical illness, disability, and premature death [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="8870" xml_f="8872" txt_i="3966" txt_f="3968">17</offsets></xref><offsets xml_i="8879" xml_f="8880" txt_i="3968" txt_f="3969">,</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="8912" xml_f="8914" txt_i="3969" txt_f="3971">18</offsets></xref><offsets xml_i="8921" xml_f="8923" txt_i="3971" txt_f="3973">].</offsets></p><p><offsets xml_i="8930" xml_f="9096" txt_i="3974" txt_f="4140">MDD is actually considered to be a risk factor for the onset of type 2 diabetes mellitus (DM) â depressed adults have a 37% increased risk for the development of DM [</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="9128" xml_f="9130" txt_i="4140" txt_f="4142">19</offsets></xref><offsets xml_i="9137" xml_f="9378" txt_i="4142" txt_f="4383">]. Further studies have shown that higher levels of depression were associated with an increasing prevalence and severity of DM complications, such as insulin resistance, which is strongly associated with the risk of coronary heart disease [</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="9410" xml_f="9412" txt_i="4383" txt_f="4385">20</offsets></xref><offsets xml_i="9419" xml_f="9723" txt_i="4385" txt_f="4689">]. MDD is one of the best predictors of hospitalization rate in older diabetic patients and among diabetic patients with a high score for depression there was even a 54% higher mortality rate than among patients with lower scores on the depression scale. However, this only applies to diabetic patients [</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="9755" xml_f="9757" txt_i="4689" txt_f="4691">21</offsets></xref><offsets xml_i="9764" xml_f="9765" txt_i="4691" txt_f="4692">,</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="9797" xml_f="9799" txt_i="4692" txt_f="4694">22</offsets></xref><offsets xml_i="9806" xml_f="10017" txt_i="4694" txt_f="4905">]. Among patients with heart problems the presence of depressive symptoms can be considered a risk factor for mortality and impaired cardiovascular outcome, in particular in patients with myocardial infarction [</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="10049" xml_f="10051" txt_i="4905" txt_f="4907">23</offsets></xref><offsets xml_i="10058" xml_f="10059" txt_i="4907" txt_f="4908">,</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="10091" xml_f="10093" txt_i="4908" txt_f="4910">24</offsets></xref><offsets xml_i="10100" xml_f="10102" txt_i="4910" txt_f="4912">].</offsets></p><p><offsets xml_i="10109" xml_f="10227" txt_i="4913" txt_f="5031">Numerous studies have found an association between comorbid mental and physical disorders with higher resource costs [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="10259" xml_f="10261" txt_i="5031" txt_f="5033">12</offsets></xref><offsets xml_i="10268" xml_f="10269" txt_i="5033" txt_f="5034">,</offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="10301" xml_f="10303" txt_i="5034" txt_f="5036">25</offsets></xref><offsets xml_i="10310" xml_f="10311" txt_i="5036" txt_f="5037">-</offsets><xref ref-type="bibr" rid="B27"><offsets xml_i="10343" xml_f="10345" txt_i="5037" txt_f="5039">27</offsets></xref><offsets xml_i="10352" xml_f="10434" txt_i="5039" txt_f="5121">]. Panzarino even states that MDD is one of the most costly illnesses in the USA [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="10466" xml_f="10468" txt_i="5121" txt_f="5123">11</offsets></xref><offsets xml_i="10475" xml_f="10669" txt_i="5123" txt_f="5317">]. When looking at more specific types of costs, i.e. number of visits to a physician or the length of stay in a hospital, however, the picture is less clear, and the findings are inconsistent [</offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="10701" xml_f="10703" txt_i="5317" txt_f="5319">25</offsets></xref><offsets xml_i="10710" xml_f="10712" txt_i="5319" txt_f="5321">].</offsets></p><p><offsets xml_i="10719" xml_f="11054" txt_i="5322" txt_f="5657">Outpatients of a general hospital often suffer from a chronic condition. Competing demands might hamper recognition of depression in the general hospital outpatient setting in the case of chronically ill patients. Depression is still the most under-recognized and under-treated psychiatric disorder in patients with a chronic illness [</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="11086" xml_f="11088" txt_i="5657" txt_f="5659">28</offsets></xref><offsets xml_i="11095" xml_f="11097" txt_i="5659" txt_f="5661">].</offsets></p><p><offsets xml_i="11104" xml_f="11194" txt_i="5662" txt_f="5752">In 2005, the multidisciplinary guideline for depression was published in the Netherlands [</offsets><xref ref-type="bibr" rid="B29"><offsets xml_i="11226" xml_f="11228" txt_i="5752" txt_f="5754">29</offsets></xref><offsets xml_i="11235" xml_f="11694" txt_i="5754" txt_f="6213">]. In this guideline, several evidence-based methods of treatment for MDD are listed, such as biological treatments, psychotherapeutic interventions, and supporting and structuring interventions. Although no specific attention was paid to the role of physical comorbidity in the guideline, the presence of physical comorbidity has been found to have no effect on the choice of treatment for MDD nor does it have an adverse effect on the outcome of treatment [</offsets><xref ref-type="bibr" rid="B30"><offsets xml_i="11726" xml_f="11728" txt_i="6213" txt_f="6215">30</offsets></xref><offsets xml_i="11735" xml_f="11736" txt_i="6215" txt_f="6216">,</offsets><xref ref-type="bibr" rid="B31"><offsets xml_i="11768" xml_f="11770" txt_i="6216" txt_f="6218">31</offsets></xref><offsets xml_i="11777" xml_f="11778" txt_i="6218" txt_f="6219">]</offsets></p><p><offsets xml_i="11785" xml_f="11988" txt_i="6220" txt_f="6423">Early detection of mental or physical conditions that does lead to effective treatment increases the possibility of remission. The longer MDD remains untreated, the more difficult the treatment becomes [</offsets><xref ref-type="bibr" rid="B32"><offsets xml_i="12020" xml_f="12022" txt_i="6423" txt_f="6425">32</offsets></xref><offsets xml_i="12029" xml_f="12381" txt_i="6425" txt_f="6777">]. This is even more the case with respect to serious comorbid physical illness, because physical and mental disorders can negatively influence each other's course. Nevertheless, Hyman states that approximately 90% of patients respond positively to an appropriate treatment if it is provided in the required intensity and for the right length of time [</offsets><xref ref-type="bibr" rid="B33"><offsets xml_i="12413" xml_f="12415" txt_i="6777" txt_f="6779">33</offsets></xref><offsets xml_i="12422" xml_f="12563" txt_i="6779" txt_f="6920">]. Simon reviewed the social and economic burden of mood disorders, and found that MDD is associated with significant functional impairment [</offsets><xref ref-type="bibr" rid="B34"><offsets xml_i="12595" xml_f="12597" txt_i="6920" txt_f="6922">34</offsets></xref><offsets xml_i="12604" xml_f="12810" txt_i="6922" txt_f="7128">]. However, he also found that effective treatment helped to restore these functions. This stresses the importance of educating physicians and nurses in the diagnosis and treatment of psychiatric disorders.</offsets></p><p><offsets xml_i="12817" xml_f="13111" txt_i="7129" txt_f="7423">The organisation of care for comorbid physically and mentally ill patients is challenging. New concepts integrating medical and psychiatric treatment have been designed to provide care for patients with complicated medical and psychiatric disorders, so-called medical psychiatric units (MPUs) [</offsets><xref ref-type="bibr" rid="B35"><offsets xml_i="13143" xml_f="13145" txt_i="7423" txt_f="7425">35</offsets></xref><offsets xml_i="13152" xml_f="13355" txt_i="7425" txt_f="7628">]. Kishi and Kathol found that in type IV type of these units, improvement in medical symptoms was comparable with improvement in general hospital wards, but that the psychiatric symptoms improved more [</offsets><xref ref-type="bibr" rid="B36"><offsets xml_i="13387" xml_f="13389" txt_i="7628" txt_f="7630">36</offsets></xref><offsets xml_i="13396" xml_f="13398" txt_i="7630" txt_f="7632">].</offsets></p><p><offsets xml_i="13405" xml_f="13674" txt_i="7633" txt_f="7902">A relatively new approach in the treatment of chronic illnesses is the so-called disease management program (DMP). A DMP can be defined as a co-ordinated unit of clinical care for chronically ill patients who are still able to actively participate in the intervention [</offsets><xref ref-type="bibr" rid="B37"><offsets xml_i="13706" xml_f="13708" txt_i="7902" txt_f="7904">37</offsets></xref><offsets xml_i="13715" xml_f="13894" txt_i="7904" txt_f="8083">]. A DMP is a frequently used approach in the treatment of illnesses such as DM, arthritis, HIV/AIDS, and COPD. DMPs are also currently available for the treatment of depression [</offsets><xref ref-type="bibr" rid="B37"><offsets xml_i="13926" xml_f="13928" txt_i="8083" txt_f="8085">37</offsets></xref><offsets xml_i="13935" xml_f="14269" txt_i="8085" txt_f="8419">]. Several studies have shown that a DMP for patients suffering from depression is superior compared to care as usual (CAU), in terms of reducing the severity of the depression, enhancing quality of life, maintaining employment, and adherence to medication (for at least 90 days). It has also been found to be cost-effective as well [</offsets><xref ref-type="bibr" rid="B37"><offsets xml_i="14301" xml_f="14303" txt_i="8419" txt_f="8421">37</offsets></xref><offsets xml_i="14310" xml_f="14311" txt_i="8421" txt_f="8422">-</offsets><xref ref-type="bibr" rid="B39"><offsets xml_i="14343" xml_f="14345" txt_i="8422" txt_f="8424">39</offsets></xref><offsets xml_i="14352" xml_f="14354" txt_i="8424" txt_f="8426">].</offsets></p><p><offsets xml_i="14361" xml_f="14440" txt_i="8427" txt_f="8506">In the USA, a new concept, the 'collaborative care intervention' is developed [</offsets><xref ref-type="bibr" rid="B40"><offsets xml_i="14472" xml_f="14474" txt_i="8506" txt_f="8508">40</offsets></xref><offsets xml_i="14481" xml_f="15049" txt_i="8508" txt_f="9076">]. Collaborative care is based on the principles of disease management and involves three main principles: firstly, active collaboration of the patient with the treatment; secondly, chained care with a built-in improvement cycle (also called 'stepped care'); and thirdly, collaboration between various medical disciplines. Katon et al. found that a collaborative care intervention, based on the 'Improving Mood-Promoting Access to Collaborative Treatment' (IMPACT) of depression for older adults with DM, was associated with more depression-free days and lower costs [</offsets><xref ref-type="bibr" rid="B41"><offsets xml_i="15081" xml_f="15083" txt_i="9076" txt_f="9078">41</offsets></xref><offsets xml_i="15090" xml_f="15387" txt_i="9078" txt_f="9375">]. The IMPACT intervention consisted of a behavioural activation intervention, Problem Solving Treatment (PST) and antidepressant medication. The long-term effect of the collaborative care intervention was still associated with sustained improvement after 12 months in two-thirds of the patients [</offsets><xref ref-type="bibr" rid="B40"><offsets xml_i="15419" xml_f="15421" txt_i="9375" txt_f="9377">40</offsets></xref><offsets xml_i="15428" xml_f="15602" txt_i="9377" txt_f="9551">]. The intervention further resulted in reducing the severity of the depression over time and higher satisfaction with the care provided, compared to patients receiving CAU [</offsets><xref ref-type="bibr" rid="B42"><offsets xml_i="15634" xml_f="15636" txt_i="9551" txt_f="9553">42</offsets></xref><offsets xml_i="15643" xml_f="15941" txt_i="9553" txt_f="9851">]. Another study evaluating the IMPACT intervention among older adults with and without comorbid physical illnesses showed that treatment was equally effective in both groups. Hence, the presence of multiple comorbid physical illnesses had no effect on the outcome of the treatment for depression [</offsets><xref ref-type="bibr" rid="B31"><offsets xml_i="15973" xml_f="15975" txt_i="9851" txt_f="9853">31</offsets></xref><offsets xml_i="15982" xml_f="15984" txt_i="9853" txt_f="9855">].</offsets></p><p><offsets xml_i="15991" xml_f="16834" txt_i="9856" txt_f="10699">In conclusion, patients with chronic physical illnesses often experience depressive symptoms. MDD is not merely a secondary side-effect of a physical illness, but must be considered as a serious comorbid mental illness. The presence of depression has a negative effect on quality of life and increases morbidity, mortality and health care costs. However, early diagnosis and well-organized treatment of depression can have a positive influence on the costs, course, and side-effects of depression. In physically ill patients, the care has to be organized in such a way that the link with the general health care treatment can be good. Previous studies have shown that DMPs can be implemented successfully in the treatment of several â especially chronic â diseases; however, comorbid mental illnesses are not addressed in current DMP programs.</offsets></p><p><offsets xml_i="16841" xml_f="17115" txt_i="10700" txt_f="10974">The present study will focus on patients suffering from three prevalent chronic physical diseases, namely DM, COPD, and cardiovascular diseases (CVD). Earlier studies have shown that these patients more frequently suffer from depression, compared to the general population [</offsets><xref ref-type="bibr" rid="B43"><offsets xml_i="17147" xml_f="17149" txt_i="10974" txt_f="10976">43</offsets></xref><offsets xml_i="17156" xml_f="17157" txt_i="10976" txt_f="10977">-</offsets><xref ref-type="bibr" rid="B46"><offsets xml_i="17189" xml_f="17191" txt_i="10977" txt_f="10979">46</offsets></xref><offsets xml_i="17198" xml_f="18458" txt_i="10979" txt_f="12239">] Treatment in a collaborative care intervention package for depression has already been realised in primary care in the USA, and has been found to be more effective than CAU. Treatment for depression will therefore be integrated in a collaborative care intervention package incorporating the principles of DMPs for the treatment of comorbid DM, CVD, and COPD. Outpatients of a general hospital who visit the DM, CVD, or COPD clinics and who have a comorbid depressive disorder will participate in this study. The collaborative care intervention package will include contracting, PST, an antidepressant algorithm, and manual-guided self-help, according to the basic model of patient and provider adherence-enhancing techniques. The interventions will be tailored to patient preferences, and compared with well-documented CAU. All treatments included in this study have individually been proven effective. The progress of the patient will be monitored and, if necessary, the treatment will be adapted. DMPs have already been proven to be effective and cost-effective as well. The goal will be to determine whether collaborative care in the general hospital is a feasible and profitable approach in terms of effectiveness and cost-effectiveness, compared to CAU.</offsets></p></sec><sec><title><offsets xml_i="18480" xml_f="18494" txt_i="12241" txt_f="12255">Methods/Design</offsets></title><sec><title><offsets xml_i="18514" xml_f="18523" txt_i="12256" txt_f="12265">Objective</offsets></title><p><offsets xml_i="18534" xml_f="18816" txt_i="12266" txt_f="12548">The primary aim of the study is to assess the effectiveness of a collaborative care model for major depressive disorders in patients with DM, CVD, and COPD in the general hospital outpatient setting. The secondary aim is to estimate the cost-effectiveness of this treatment package.</offsets></p></sec><sec><title><offsets xml_i="18838" xml_f="18848" txt_i="12550" txt_f="12560">Hypothesis</offsets></title><p><offsets xml_i="18859" xml_f="19081" txt_i="12561" txt_f="12783">The hypothesis underlying this study is that a collaborative care model for major depressive disorder for outpatients in a general hospital setting with DM, CVD, and COPD is more effective and more cost-effective than CAU.</offsets></p></sec><sec><title><offsets xml_i="19103" xml_f="19115" txt_i="12785" txt_f="12797">Study design</offsets></title><p><offsets xml_i="19126" xml_f="19298" txt_i="12798" txt_f="12970">The study consists of a two-armed randomised controlled trial, with randomisation at patient level. The outcome parameters will be measured by a blinded research assistant.</offsets></p><p><offsets xml_i="19305" xml_f="20079" txt_i="12971" txt_f="13745">The patients in the intervention group will receive collaborative care from a consultative psychiatric nurse (CPN) and a psychiatrist in the department of psychiatry of the participating hospital. The control group will receive CAU from a general non-psychiatric nurse in the outpatient department. If patients in the control group are referred to a CPN in the department of psychiatry, a CPN who has not received training will treat them. Hence, trained CPNs will not influence the content of CAU, and will therefore not influence the outcome of the intervention. Since the patients and the CPNs are aware of the allocation, they can not be blinded. The patients will be assessed by means of self-report questionnaires, in order to avoid the occurrence of interviewer bias.</offsets></p><p><offsets xml_i="20086" xml_f="20374" txt_i="13746" txt_f="14034">General outpatient clinic nurses will be trained in screening for depressive disorders, and will screen all patients visiting the participating departments during the inclusion period. Patients not visiting the departments during the inclusion period will be screened by mail. See Figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="20404" xml_f="20405" txt_i="14034" txt_f="14035">1</offsets></xref><offsets xml_i="20412" xml_f="20429" txt_i="14035" txt_f="14052"> for a flowchart.</offsets></p><fig position="float" id="F1"><label><offsets xml_i="20470" xml_f="20478" txt_i="14053" txt_f="14061">Figure 1</offsets></label><caption><p><offsets xml_i="20498" xml_f="20665" txt_i="14061" txt_f="14228">Intervention. DM: Diabetes Mellitus, CVD: Cardiovascular Diseases, COPD: Chronic Obstructive Pulmonary Disease, CPN: Consultative Psychiatric Nurse, CAU: Care As Usual</offsets></p></caption><graphic xlink:href="1472-6963-7-28-1"></graphic></fig></sec><sec><title><offsets xml_i="20752" xml_f="20778" txt_i="14230" txt_f="14256">Recruitment of departments</offsets></title><p><offsets xml_i="20789" xml_f="20992" txt_i="14257" txt_f="14460">The study has been set up in co-operation with the Onze Lieve Vrouwe Gasthuis (OLVG) in Amsterdam. The diabetes, cardiological, and pulmonary outpatient clinics of the OLVG will participate in the study.</offsets></p><p><offsets xml_i="20999" xml_f="21214" txt_i="14461" txt_f="14676">A psychiatrist will be trained to provide the collaborative care intervention, together with a care manager. He will receive training in contracting (together with the care manager) and the antidepressant algorithm.</offsets></p><p><offsets xml_i="21221" xml_f="21721" txt_i="14677" txt_f="15177">Consultative psychiatric nurses will be trained to provide the collaborative care intervention in the role of care manager. They will receive training in monitoring, care-management, PST, and contracting. The department nurses will receive training in screening for depressive disorder. The care managers in the intervention group will be closely monitored by the research team, in order to ensure that the intervention is provided correctly. There will be no care manager for patients receiving CAU.</offsets></p></sec><sec><title><offsets xml_i="21743" xml_f="21766" txt_i="15179" txt_f="15202">Recruitment of patients</offsets></title><p><offsets xml_i="21777" xml_f="23092" txt_i="15203" txt_f="16518">All patients visiting the participating departments, who have been diagnosed with a specific chronic disease, as specified in their files, will be selected. Specific diagnoses are: DM type II in the DM department, COPD in the pulmonary department, and chronic heart failure or post-acute myocardial infarction in the cardiovascular department. Patients who meet the inclusion criteria and visit the participating departments during the inclusion period will receive an information letter, an informed consent form and the screening questionnaire (depression subscale of the 'Patient Health Questionnaire' â PHQ-9). Patients who screen positive for depression will then receive the baseline questionnaire. Patients who meet the inclusion criteria, but do not visit the participating departments will receive a package by mail which includes an information letter, an informed consent form, the screening instrument (PHQ-9), and the baseline questionnaire. In the information letter the patients are asked if they are willing to participate in a Trimbos Institute study investigating mental problems and treatment options in the general hospital setting. If they agree to participate, they will be asked to sign the informed consent form and to return it together with the completed questionnaires to the researchers.</offsets></p><p><offsets xml_i="23099" xml_f="23229" txt_i="16519" txt_f="16649">Patients will be included in the study if they reach a cut-off score of 15 (moderate to severe depressive disorder) on the PHQ-9 [</offsets><xref ref-type="bibr" rid="B47"><offsets xml_i="23261" xml_f="23263" txt_i="16649" txt_f="16651">47</offsets></xref><offsets xml_i="23270" xml_f="23429" txt_i="16651" txt_f="16810">]. For patients who reach the cut-off score, the MINI-International Neuropsychiatric Interview (MINI) will also be held by telephone to classify the symptoms [</offsets><xref ref-type="bibr" rid="B48"><offsets xml_i="23461" xml_f="23463" txt_i="16810" txt_f="16812">48</offsets></xref><offsets xml_i="23470" xml_f="23471" txt_i="16812" txt_f="16813">,</offsets><xref ref-type="bibr" rid="B49"><offsets xml_i="23503" xml_f="23505" txt_i="16813" txt_f="16815">49</offsets></xref><offsets xml_i="23512" xml_f="23642" txt_i="16815" txt_f="16945">] The MINI is a brief validated and structured diagnostic psychiatric interview to assess DSM-IV and ICD-10 psychiatric disorders.</offsets></p><p><offsets xml_i="23649" xml_f="24087" txt_i="16946" txt_f="17384">In the same interview, the patients will be asked if the symptoms have been present for at least 6 weeks, can be diagnosed as major depressive disorder, and lead to general dysfunction with serious problems in at least one of the following: work, household, activities, or relationship. Therefore, the aim is to include chronically ill patients with a moderate to severe depressive disorder who dysfunction due to the depressive disorder.</offsets></p><p><offsets xml_i="24094" xml_f="24522" txt_i="17385" txt_f="17813">For patients who are assigned to the intervention group a consultation will be arranged, first with the care manager and then with a psychiatrist, to provide more information about the treatment and to formulate a treatment plan together (contracting). Patients assigned to the CAU group will be told that they can consult their general practitioner if they feel that they need treatment, and they will be monitored (see Figure </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="24552" xml_f="24553" txt_i="17813" txt_f="17814">2</offsets></xref><offsets xml_i="24560" xml_f="24786" txt_i="17814" txt_f="18040"> for a schematic diagram). Patients will only be included in the study after they have given written informed consent. The Medical Ethical Committee of the Onze Lieve Vrouwe Gasthuis has approved the trial (study no WO06-066).</offsets></p><fig position="float" id="F2"><label><offsets xml_i="24827" xml_f="24835" txt_i="18041" txt_f="18049">Figure 2</offsets></label><caption><p><offsets xml_i="24855" xml_f="24954" txt_i="18049" txt_f="18148">Flowchart. PHQ-9: Patient Health Questionnaire, MINI: MINI-International Neuropsychiatric Interview</offsets></p></caption><graphic xlink:href="1472-6963-7-28-2"></graphic></fig></sec><sec><title><offsets xml_i="25041" xml_f="25067" txt_i="18150" txt_f="18176">Patient exclusion criteria</offsets></title><p><offsets xml_i="25078" xml_f="25434" txt_i="18177" txt_f="18533">Patients will be excluded from the study if they: have insufficient knowledge of the Dutch language to fill in the questionnaires, have a serious mental impairment, are already receiving psychiatric treatment, suffer from dementia, delirium or bipolar disorder, are addicted to drugs or alcohol, are psychotic or suicidal, and/or are under 18 years of age.</offsets></p></sec><sec><title><offsets xml_i="25456" xml_f="25469" txt_i="18535" txt_f="18548">Randomisation</offsets></title><p><offsets xml_i="25480" xml_f="25861" txt_i="18549" txt_f="18930">Patients in the participating departments who screened positive on the PHQ-9 and who have an MDD, according to the MINI, will be randomly allocated to the intervention group or the CAU group within their policlinic. Randomisation will be performed by the researcher, using a computerized method to avoid assignment bias. The patients will not be blinded for their group allocation.</offsets></p></sec><sec><title><offsets xml_i="25883" xml_f="25929" txt_i="18932" txt_f="18978">Embedding in the general hospital care setting</offsets></title><p><offsets xml_i="25940" xml_f="26266" txt_i="18979" txt_f="19305">The collaborative care framework used in this study will last for a maximum of 22 weeks, and comprises the following four elements: a) contracting, b) antidepressant medication, c) PST, and d) manual-guided self-help. These treatments are superimposed on the basic model of patient and provider adherence-enhancing techniques.</offsets></p><p><offsets xml_i="26273" xml_f="26599" txt_i="19306" txt_f="19632">The diabetes, cardiology, and pulmonary outpatient clinics of the OLVG will participate in this study. The elements of the collaborative care framework are divided among different disciplines in order to maximize effect of the interventions. The elements provided by each discipline performing the elements are shown in Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="26631" xml_f="26632" txt_i="19632" txt_f="19633">1</offsets></xref><offsets xml_i="26639" xml_f="26640" txt_i="19633" txt_f="19634">:</offsets></p><table-wrap position="float" id="T1"><label><offsets xml_i="26688" xml_f="26695" txt_i="19635" txt_f="19642">Table 1</offsets></label><caption><p><offsets xml_i="26715" xml_f="26748" txt_i="19642" txt_f="19675">Embedding in the hospital setting</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><offsets xml_i="26827" xml_f="26831" txt_i="19676" txt_f="19680">Task</offsets></td><td align="left"><offsets xml_i="26853" xml_f="26863" txt_i="19681" txt_f="19691">Discipline</offsets></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="26909" xml_f="26918" txt_i="19692" txt_f="19701">Screening</offsets></td><td align="left"><offsets xml_i="26940" xml_f="26967" txt_i="19702" txt_f="19729">Department nurse/Researcher</offsets></td></tr><tr><td align="left"><offsets xml_i="26998" xml_f="27008" txt_i="19730" txt_f="19740">Contractor</offsets></td><td align="left"><offsets xml_i="27030" xml_f="27074" txt_i="19741" txt_f="19785">Psychiatrist/Consultative psychiatric nurses</offsets></td></tr><tr><td align="left"><offsets xml_i="27105" xml_f="27117" txt_i="19786" txt_f="19798">Care manager</offsets></td><td align="left"><offsets xml_i="27139" xml_f="27170" txt_i="19799" txt_f="19830">Consultative psychiatric nurses</offsets></td></tr><tr><td align="left"><offsets xml_i="27201" xml_f="27232" txt_i="19831" txt_f="19862">Prescription of antidepressants</offsets></td><td align="left"><offsets xml_i="27254" xml_f="27266" txt_i="19863" txt_f="19875">Psychiatrist</offsets></td></tr><tr><td align="left"><offsets xml_i="27297" xml_f="27322" txt_i="19876" txt_f="19901">Problem Solving Treatment</offsets></td><td align="left"><offsets xml_i="27344" xml_f="27375" txt_i="19902" txt_f="19933">Consultative psychiatric nurses</offsets></td></tr></tbody></table></table-wrap></sec><sec><title><offsets xml_i="27432" xml_f="27444" txt_i="19935" txt_f="19947">Intervention</offsets></title><p><offsets xml_i="27455" xml_f="27512" txt_i="19948" txt_f="20005">The intervention is based on a collaborative care model [</offsets><xref ref-type="bibr" rid="B40"><offsets xml_i="27544" xml_f="27546" txt_i="20005" txt_f="20007">40</offsets></xref><offsets xml_i="27553" xml_f="27554" txt_i="20007" txt_f="20008">,</offsets><xref ref-type="bibr" rid="B50"><offsets xml_i="27586" xml_f="27588" txt_i="20008" txt_f="20010">50</offsets></xref><offsets xml_i="27595" xml_f="27596" txt_i="20010" txt_f="20011">-</offsets><xref ref-type="bibr" rid="B52"><offsets xml_i="27628" xml_f="27630" txt_i="20011" txt_f="20013">52</offsets></xref><offsets xml_i="27637" xml_f="27678" txt_i="20013" txt_f="20054">]., which involves three main principles:</offsets></p><p><offsets xml_i="27685" xml_f="27688" txt_i="20055" txt_f="20058">1. </offsets><italic><offsets xml_i="27696" xml_f="27750" txt_i="20058" txt_f="20112">Active collaboration of the patient with the treatment</offsets></italic><offsets xml_i="27759" xml_f="28025" txt_i="20112" txt_f="20378">. In order to investigate the motivation of the patient, the psychiatrist has to ask himself the following question: What should I do to motivate the patient to participate in this study? This principle will be addressed in the contracting phase by the psychiatrist.</offsets></p><p><offsets xml_i="28032" xml_f="28035" txt_i="20379" txt_f="20382">2. </offsets><italic><offsets xml_i="28043" xml_f="28118" txt_i="20382" txt_f="20457">Chained care with a built-in improvement cycle (also called 'stepped care')</offsets></italic><offsets xml_i="28127" xml_f="28337" txt_i="20457" txt_f="20667">. This means that each individual step which is taken in the treatment will be evaluated. Based on the results, the next step will be undertaken, tailored to the patient's needs by the psychiatrist and the CPN.</offsets></p><p><offsets xml_i="28344" xml_f="28347" txt_i="20668" txt_f="20671">3. </offsets><italic><offsets xml_i="28355" xml_f="28404" txt_i="20671" txt_f="20720">Collaboration between various medical disciplines</offsets></italic><offsets xml_i="28413" xml_f="28561" txt_i="20720" txt_f="20868">. The medical specialists, the department nurses, the CPNs, and the psychiatrist all work together in the diagnosis and/or treatment of the patient.</offsets></p></sec><sec><title><offsets xml_i="28583" xml_f="28591" txt_i="20870" txt_f="20878">Training</offsets></title><p><offsets xml_i="28602" xml_f="29022" txt_i="20879" txt_f="21299">Since the treatment involves a collaborative care approach, the psychiatrist participating in the study will receive training in collaborative care, i.e. contracting and the antidepressant algorithm. The CPNs who will function as care manager will receive training in monitoring, care-management, PST, and contracting at the start of the study and the department nurses will receive training in screening for depression.</offsets></p><p><offsets xml_i="29029" xml_f="29229" txt_i="21300" txt_f="21500">The training will be provided by members of the research group who, in turn, were trained by the IMPACT research group from Seattle, the developers of the collaborative care model used in this study [</offsets><xref ref-type="bibr" rid="B53"><offsets xml_i="29261" xml_f="29263" txt_i="21500" txt_f="21502">53</offsets></xref><offsets xml_i="29270" xml_f="29272" txt_i="21502" txt_f="21504">].</offsets></p></sec><sec><title><offsets xml_i="29294" xml_f="29341" txt_i="21506" txt_f="21553">Treatment of patients in the intervention group</offsets></title><p><offsets xml_i="29352" xml_f="29359" txt_i="21554" txt_f="21561">In the </offsets><italic><offsets xml_i="29367" xml_f="29396" txt_i="21561" txt_f="21590">collaborative care framework </offsets></italic><offsets xml_i="29405" xml_f="30079" txt_i="21590" txt_f="22264">used in this study, active collaboration of the patient with the treatment is enhanced. The care is tailored to the patient's needs within an active team, which consists of the patient, the care manager and the consulting psychiatrist. If the care manager experiences difficulties in this process, (s)he can consult the psychiatrist. Within the team the need for and assessment of the required treatment will be determined, and a treatment plan will be formulated. Subsequently, the care managers will co-ordinate the care and evaluate each step, together with the patient. According to the stepped care principle, treatment response will be monitored once every two weeks [</offsets><xref ref-type="bibr" rid="B54"><offsets xml_i="30111" xml_f="30113" txt_i="22264" txt_f="22266">54</offsets></xref><offsets xml_i="30120" xml_f="30513" txt_i="22266" txt_f="22659">]. If necessary, each treatment step will be followed by a subsequent step to improve the outcome. For patients who solely receive PST, this subsequent step can involve six extra sessions of PST and/or adding antidepressant medication (AD), or switching to antidepressant medication only. The same method will be applied to patients who are treated with both PST and antidepressant medication.</offsets></p><p><offsets xml_i="30520" xml_f="30548" txt_i="22660" txt_f="22688">The framework also includes </offsets><italic><offsets xml_i="30556" xml_f="30607" txt_i="22688" txt_f="22739">patient and provider adherence-improving techniques</offsets></italic><offsets xml_i="30616" xml_f="30942" txt_i="22739" txt_f="23065">. Provider adherence-improving interventions are administered by the research group. Provider adherence has been enhanced in an earlier study in primary care, in which psychiatrists instructed general practitioners by means of consultations, combined with phone calls and written instructions that were distributed regularly [</offsets><xref ref-type="bibr" rid="B55"><offsets xml_i="30974" xml_f="30976" txt_i="23065" txt_f="23067">55</offsets></xref><offsets xml_i="30983" xml_f="31059" txt_i="23067" txt_f="23143">]. Such an approach was also found to be feasible and effective in the USA [</offsets><xref ref-type="bibr" rid="B56"><offsets xml_i="31091" xml_f="31093" txt_i="23143" txt_f="23145">56</offsets></xref><xref ref-type="bibr" rid="B55"><offsets xml_i="31132" xml_f="31134" txt_i="23145" txt_f="23147">55</offsets></xref><offsets xml_i="31141" xml_f="31142" txt_i="23147" txt_f="23148">,</offsets><xref ref-type="bibr" rid="B57"><offsets xml_i="31174" xml_f="31176" txt_i="23148" txt_f="23150">57</offsets></xref><offsets xml_i="31183" xml_f="31185" txt_i="23150" txt_f="23152">].</offsets></p><p><offsets xml_i="31192" xml_f="31467" txt_i="23153" txt_f="23428">In the present setting, the collaborative care framework includes four treatment options superimposed on adherence-enhancing techniques. The patients will have the choice of receiving antidepressant medication, but PST, contracting and manual-guided self-help are obligatory.</offsets></p><sec><title><offsets xml_i="31483" xml_f="31500" txt_i="23429" txt_f="23446">Ad a) Contracting</offsets></title><p><offsets xml_i="31511" xml_f="32185" txt_i="23447" txt_f="24121">The care manager and the consultant psychiatrist in the hospital together inform the patient that the diagnosis is a depressive disorder. The patient will receive psycho-education about the course and the treatment options, and is offered the choice of evidence and guideline-based treatments. Depending on the patient's preferences, a joint treatment contract is formulated by the psychiatrist, the care manager and the patient. The aim of the contract is to make clear that the treatment arrangements must be adhered to by all parties involved. In an earlier study in the Netherlands, based on a collaborative care model, collaboration was indeed enhanced by contracting [</offsets><xref ref-type="bibr" rid="B55"><offsets xml_i="32217" xml_f="32219" txt_i="24121" txt_f="24123">55</offsets></xref><offsets xml_i="32226" xml_f="32228" txt_i="24123" txt_f="24125">].</offsets></p><p><offsets xml_i="32235" xml_f="32730" txt_i="24126" txt_f="24621">During the intervention phase, the patient is asked to fill in the PHQ-9 ahead of every appointment in order to evaluate the progress. The treatment steps are evaluated with the care manager. If a patient is not satisfied with the chosen treatment, (s)he can change to another form of treatment, and this will be confirmed in a new contract. If a patient wishes to withdraw from the intervention, (s)he will continue to receive CAU. All treatment choices are well documented as process measures.</offsets></p></sec><sec><title><offsets xml_i="32752" xml_f="32782" txt_i="24623" txt_f="24653">Ad b) Antidepressant algorithm</offsets></title><p><offsets xml_i="32793" xml_f="33050" txt_i="24654" txt_f="24911">An earlier study in the USA reported that only 46% of outpatients with care management who were treated with antidepressants at their local academic medical centre received adequate antidepressant treatment, thus reflecting a minimum standard of treatment [</offsets><xref ref-type="bibr" rid="B58"><offsets xml_i="33082" xml_f="33084" txt_i="24911" txt_f="24913">58</offsets></xref><offsets xml_i="33091" xml_f="33214" txt_i="24913" txt_f="25036">]. There are further indications that chronically ill patients may require individually tailored antidepressant treatment [</offsets><xref ref-type="bibr" rid="B59"><offsets xml_i="33246" xml_f="33248" txt_i="25036" txt_f="25038">59</offsets></xref><offsets xml_i="33255" xml_f="33566" txt_i="25038" txt_f="25349">]. Therefore, to enhance efficiency and adherence to the medication, a step-up antidepressant algorithm will be tailored to patients with DM, CVD, and COPD, consisting of two different types of antidepressant medication, i.e. selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs).</offsets></p><p><offsets xml_i="33573" xml_f="34337" txt_i="25350" txt_f="26114">Two antidepressants will be tested in two periods of nine weeks. If, after 18 weeks there is no improvement, the patient will be offered different kinds of treatment. In the choice of antidepressants, interactions with medication for chronic illnesses and potential palliative side-effects have been taken into consideration. If a patient is already taking antidepressants, but is still suffering from depression, the treatment is considered to be unsatisfactory, and after the required wash-out period of several weeks, the algorithm will commence. The PHQ-9 will be used to screen for and monitor the course of depression. The feasibility of the PHQ-9 to evaluate and guide a step-up algorithm has already been proven in outpatients in the primary care setting [</offsets><xref ref-type="bibr" rid="B40"><offsets xml_i="34369" xml_f="34371" txt_i="26114" txt_f="26116">40</offsets></xref><offsets xml_i="34378" xml_f="34379" txt_i="26116" txt_f="26117">,</offsets><xref ref-type="bibr" rid="B60"><offsets xml_i="34411" xml_f="34413" txt_i="26117" txt_f="26119">60</offsets></xref><offsets xml_i="34420" xml_f="34738" txt_i="26119" txt_f="26437">] Therefore, in the present study, the PHQ-9 will be used in the same way. The care managers will discuss the effects of the medication and the potential side-effects with the patient, and report to the psychiatrist. The psychiatrist will follow this process closely to determine whether the treatment is satisfactory.</offsets></p><p><offsets xml_i="34745" xml_f="34992" txt_i="26438" txt_f="26685">Earlier studies have shown that the prescription of antidepressants for patients suffering from DM type I and II is safe and effective. Certain SSRIs, such as duloxetine, may also even be effective in the treatment of painful diabetic neuropathy [</offsets><xref ref-type="bibr" rid="B61"><offsets xml_i="35024" xml_f="35026" txt_i="26685" txt_f="26687">61</offsets></xref><offsets xml_i="35033" xml_f="35034" txt_i="26687" txt_f="26688">,</offsets><xref ref-type="bibr" rid="B62"><offsets xml_i="35066" xml_f="35068" txt_i="26688" txt_f="26690">62</offsets></xref><offsets xml_i="35075" xml_f="35284" txt_i="26690" txt_f="26899">]. However, knowledge about the interaction and side-effects of antidepressants in chronically ill patients has not yet been structured into a protocol tailored to the needs of patients with DM, CVD, and COPD.</offsets></p></sec><sec><title><offsets xml_i="35306" xml_f="35343" txt_i="26901" txt_f="26938">Ad c) Problem Solving Treatment (PST)</offsets></title><p><offsets xml_i="35354" xml_f="35477" txt_i="26939" txt_f="27062">Hawton and Kirkhave developed a brief psychological intervention based on the Problem Solving Therapy by D'Zurilla et al. [</offsets><xref ref-type="bibr" rid="B63"><offsets xml_i="35509" xml_f="35511" txt_i="27062" txt_f="27064">63</offsets></xref><offsets xml_i="35518" xml_f="35587" txt_i="27064" txt_f="27133">] that uses the behavioural perspective, but is less time-consuming [</offsets><xref ref-type="bibr" rid="B64"><offsets xml_i="35619" xml_f="35621" txt_i="27133" txt_f="27135">64</offsets></xref><offsets xml_i="35628" xml_f="35897" txt_i="27135" txt_f="27404">]. PST will be administered by nurses in 6â12 sessions, depending on the progress according to the PHQ-9 scale. The problem-solving approach consists of seven stages, and is based on the assumption that emotional problems are often induced by problems in everyday life.</offsets></p><p><offsets xml_i="35904" xml_f="36021" txt_i="27405" txt_f="27522">Problem Solving Treatment has been found to be effective for treating MDD when provided by trained community nurses [</offsets><xref ref-type="bibr" rid="B65"><offsets xml_i="36053" xml_f="36055" txt_i="27522" txt_f="27524">65</offsets></xref><offsets xml_i="36062" xml_f="36223" txt_i="27524" txt_f="27685">]. It is further significantly more effective than placebo treatment, and also more effective than antidepressant medication alone for patients in primary care [</offsets><xref ref-type="bibr" rid="B66"><offsets xml_i="36255" xml_f="36257" txt_i="27685" txt_f="27687">66</offsets></xref><offsets xml_i="36264" xml_f="36266" txt_i="27687" txt_f="27689">].</offsets></p><p><offsets xml_i="36273" xml_f="36467" txt_i="27690" txt_f="27884">The first session of PST will last for one hour, in which a clear focus of the treatment is established, based on the patient's current problems. Follow-up sessions will last for thirty minutes.</offsets></p></sec><sec><title><offsets xml_i="36489" xml_f="36518" txt_i="27886" txt_f="27915">Ad d) Manual-guided self-help</offsets></title><p><offsets xml_i="36529" xml_f="37092" txt_i="27916" txt_f="28479">The patient will receive a standardised treatment manual, specifically tailored to coping with depression and chronic illness, and will work through this manual. It consists of various chapters, focusing on relaxation, sleeping, exercise and cognitions, and it also gives dietary suggestions. The progress made by the patient is discussed every week or every other week between the patient and the care manager. Willemse et al. found that this kind of intervention is more effective than CAU, at least for patients in primary care with a sub-clinical depression [</offsets><xref ref-type="bibr" rid="B67"><offsets xml_i="37124" xml_f="37126" txt_i="28479" txt_f="28481">67</offsets></xref><offsets xml_i="37133" xml_f="37237" txt_i="28481" txt_f="28585">]. Relaxation therapy on its own has been found to be useful as a complementary approach to depression [</offsets><xref ref-type="bibr" rid="B29"><offsets xml_i="37269" xml_f="37271" txt_i="28585" txt_f="28587">29</offsets></xref><offsets xml_i="37278" xml_f="37280" txt_i="28587" txt_f="28589">].</offsets></p><p><offsets xml_i="37287" xml_f="37471" txt_i="28590" txt_f="28774">Patients suffering from depression often experience difficulties in the sleep-wake-rhythm. The presence of these difficulties is also one of the criteria in the classification of MDD [</offsets><xref ref-type="bibr" rid="B68"><offsets xml_i="37503" xml_f="37505" txt_i="28774" txt_f="28776">68</offsets></xref><offsets xml_i="37512" xml_f="37624" txt_i="28776" txt_f="28888">]. DM patients with painful peripheral neuropathy were also found to suffer considerably from sleeping problems[</offsets><xref ref-type="bibr" rid="B69"><offsets xml_i="37656" xml_f="37658" txt_i="28888" txt_f="28890">69</offsets></xref><offsets xml_i="37665" xml_f="37871" txt_i="28890" txt_f="29096">]. For patients with chronic illnesses, sleeping problems are significantly correlated with poorer mental health, diminished work productivity and work quality, and greater use of the health care services [</offsets><xref ref-type="bibr" rid="B70"><offsets xml_i="37903" xml_f="37905" txt_i="29096" txt_f="29098">70</offsets></xref><offsets xml_i="37912" xml_f="38005" txt_i="29098" txt_f="29191">]. Hence, the treatment of sleeping problems will be an important focus of this intervention.</offsets></p><p><offsets xml_i="38012" xml_f="38296" txt_i="29192" txt_f="29476">Furthermore, exercise to improve general physical condition will be stimulated. Tkachuk and Martinhave extensively reviewed studies focusing on exercise therapy for patients with psychiatric disorders, and found that exercise has a positive effect, among other things, on depression [</offsets><xref ref-type="bibr" rid="B71"><offsets xml_i="38328" xml_f="38330" txt_i="29476" txt_f="29478">71</offsets></xref><offsets xml_i="38337" xml_f="38535" txt_i="29478" txt_f="29676">]. In chronically ill patients with comorbid depression, exercise training was found to reduce the severity of the depression and to have a positive influence on indicators of illness risk factors [</offsets><xref ref-type="bibr" rid="B72"><offsets xml_i="38567" xml_f="38569" txt_i="29676" txt_f="29678">72</offsets></xref><offsets xml_i="38576" xml_f="38577" txt_i="29678" txt_f="29679">-</offsets><xref ref-type="bibr" rid="B74"><offsets xml_i="38609" xml_f="38611" txt_i="29679" txt_f="29681">74</offsets></xref><offsets xml_i="38618" xml_f="38619" txt_i="29681" txt_f="29682">]</offsets></p><p><offsets xml_i="38626" xml_f="38830" txt_i="29683" txt_f="29887">The dietary intervention will focus on a healthy diet, losing weight and on taking omega-3 fatty acids. McElroy et al. concluded in their review that an overlap exists between mood disorders and obesity [</offsets><xref ref-type="bibr" rid="B75"><offsets xml_i="38862" xml_f="38864" txt_i="29887" txt_f="29889">75</offsets></xref><offsets xml_i="38871" xml_f="39111" txt_i="29889" txt_f="30129">]. Several studies also indicate an association between omega-3 fatty acids and depression. For example, Su et al. found that omega-3 fatty acids could improve the short-term course of illness, and were well tolerated in patients with MDD [</offsets><xref ref-type="bibr" rid="B76"><offsets xml_i="39143" xml_f="39145" txt_i="30129" txt_f="30131">76</offsets></xref><offsets xml_i="39152" xml_f="39323" txt_i="30131" txt_f="30302">]. The supplementation of omega-3 fatty acids was also found to be helpful in treating depression in patients with DM type 2 and in treating patients with heart diseases [</offsets><xref ref-type="bibr" rid="B77"><offsets xml_i="39355" xml_f="39357" txt_i="30302" txt_f="30304">77</offsets></xref><offsets xml_i="39364" xml_f="39365" txt_i="30304" txt_f="30305">,</offsets><xref ref-type="bibr" rid="B78"><offsets xml_i="39397" xml_f="39399" txt_i="30305" txt_f="30307">78</offsets></xref><offsets xml_i="39406" xml_f="39407" txt_i="30307" txt_f="30308">]</offsets></p></sec></sec><sec><title><offsets xml_i="39435" xml_f="39481" txt_i="30311" txt_f="30357">Treatment of the patients in the control group</offsets></title><p><offsets xml_i="39492" xml_f="39919" txt_i="30358" txt_f="30785">Half of the included patients function as a control group, in which they will receive CAU. The actual content of the CAU treatment (e.g. medication and number of contacts with physicians) will be assessed with the 'Scale assessing contacts between patients and practitioners' ('Contacten met dokters en andere behandelaars') and the 'Scale assessing medical utilization of health services' ('Vragenlijst medische consumptie') [</offsets><xref ref-type="bibr" rid="B57"><offsets xml_i="39951" xml_f="39953" txt_i="30785" txt_f="30787">57</offsets></xref><offsets xml_i="39960" xml_f="39962" txt_i="30787" txt_f="30789">].</offsets></p></sec><sec><title><offsets xml_i="39984" xml_f="39999" txt_i="30791" txt_f="30806">Data collection</offsets></title><p><offsets xml_i="40010" xml_f="40216" txt_i="30807" txt_f="31013">Data will be collected by the Trimbos Institute in co-operation with the Onze Lieve Vrouwe Gasthuis. After giving informed consent, the patients will receive assessment questionnaires by mail at baseline (T</offsets><sub><offsets xml_i="40221" xml_f="40222" txt_i="31013" txt_f="31014">0</offsets></sub><offsets xml_i="40228" xml_f="40235" txt_i="31014" txt_f="31021">), 3 (T</offsets><sub><offsets xml_i="40240" xml_f="40241" txt_i="31021" txt_f="31022">1</offsets></sub><offsets xml_i="40247" xml_f="40254" txt_i="31022" txt_f="31029">), 6 (T</offsets><sub><offsets xml_i="40259" xml_f="40260" txt_i="31029" txt_f="31030">2</offsets></sub><offsets xml_i="40266" xml_f="40273" txt_i="31030" txt_f="31037">), 9 (T</offsets><sub><offsets xml_i="40278" xml_f="40279" txt_i="31037" txt_f="31038">3</offsets></sub><offsets xml_i="40285" xml_f="40304" txt_i="31038" txt_f="31057">), and 12 months (T</offsets><sub><offsets xml_i="40309" xml_f="40310" txt_i="31057" txt_f="31058">4</offsets></sub><offsets xml_i="40316" xml_f="40374" txt_i="31058" txt_f="31116">) after inclusion. The modified 'Tailored Design Method' [</offsets><xref ref-type="bibr" rid="B79"><offsets xml_i="40406" xml_f="40408" txt_i="31116" txt_f="31118">79</offsets></xref><offsets xml_i="40415" xml_f="40468" txt_i="31118" txt_f="31171">] will be used in this study to recruit the patients.</offsets></p></sec><sec><title><offsets xml_i="40490" xml_f="40508" txt_i="31173" txt_f="31191">Outcome parameters</offsets></title><p><offsets xml_i="40519" xml_f="40732" txt_i="31192" txt_f="31405">The use of questionnaires in the hospital setting has a long tradition. Several of the questionnaires used in this study have already been used for earlier studies of patients in the hospital setting (e.g. PHQ-9 [</offsets><xref ref-type="bibr" rid="B80"><offsets xml_i="40764" xml_f="40766" txt_i="31405" txt_f="31407">80</offsets></xref><offsets xml_i="40773" xml_f="40784" txt_i="31407" txt_f="31418">], IDS-SR [</offsets><xref ref-type="bibr" rid="B81"><offsets xml_i="40816" xml_f="40818" txt_i="31418" txt_f="31420">81</offsets></xref><offsets xml_i="40825" xml_f="40835" txt_i="31420" txt_f="31430">], SF-36 [</offsets><xref ref-type="bibr" rid="B82"><offsets xml_i="40867" xml_f="40869" txt_i="31430" txt_f="31432">82</offsets></xref><offsets xml_i="40876" xml_f="41104" txt_i="31432" txt_f="31660">]) and proved feasible. Although physical symptoms such as fatigue could be misinterpreted as depressive symptoms, in outpatients with general physical disorders no other diagnostic criteria for the diagnosis of MDD are needed [</offsets><xref ref-type="bibr" rid="B83"><offsets xml_i="41136" xml_f="41138" txt_i="31660" txt_f="31662">83</offsets></xref><offsets xml_i="41145" xml_f="41146" txt_i="31662" txt_f="31663">,</offsets><xref ref-type="bibr" rid="B84"><offsets xml_i="41178" xml_f="41180" txt_i="31663" txt_f="31665">84</offsets></xref><offsets xml_i="41187" xml_f="41189" txt_i="31665" txt_f="31667">].</offsets></p><p><offsets xml_i="41196" xml_f="41253" txt_i="31668" txt_f="31725">Baseline measurements will take place before inclusion (T</offsets><sub><offsets xml_i="41258" xml_f="41259" txt_i="31725" txt_f="31726">0</offsets></sub><offsets xml_i="41265" xml_f="41367" txt_i="31726" txt_f="31828">). The first follow-up measurement will take place at the end of the treatment, i.e. after 3 months (T</offsets><sub><offsets xml_i="41372" xml_f="41373" txt_i="31828" txt_f="31829">1</offsets></sub><offsets xml_i="41379" xml_f="41443" txt_i="31829" txt_f="31893">), and further follow-up measurements will take place after 6 (T</offsets><sub><offsets xml_i="41448" xml_f="41449" txt_i="31893" txt_f="31894">2</offsets></sub><offsets xml_i="41455" xml_f="41462" txt_i="31894" txt_f="31901">), 9 (T</offsets><sub><offsets xml_i="41467" xml_f="41468" txt_i="31901" txt_f="31902">3</offsets></sub><offsets xml_i="41474" xml_f="41492" txt_i="31902" txt_f="31920">) and 12 months (T</offsets><sub><offsets xml_i="41497" xml_f="41498" txt_i="31920" txt_f="31921">4</offsets></sub><offsets xml_i="41504" xml_f="41506" txt_i="31921" txt_f="31923">).</offsets></p><sec><title><offsets xml_i="41522" xml_f="41548" txt_i="31924" txt_f="31950">1. Primary outcome measure</offsets></title><sec><title><offsets xml_i="41568" xml_f="41599" txt_i="31951" txt_f="31982">Severity of depressive symptoms</offsets></title><p><offsets xml_i="41610" xml_f="41921" txt_i="31983" txt_f="32294">The severity of the depressive symptoms is the primary outcome, and will be measured according to the depression sub-scale of the PHQ (PHQ-9). The PHQ-9 is a brief instrument that scores each DSM-IV criterion of a major depressive disorder on a scale ranging from zero (not at all) to three (nearly every day) [</offsets><xref ref-type="bibr" rid="B47"><offsets xml_i="41953" xml_f="41955" txt_i="32294" txt_f="32296">47</offsets></xref><offsets xml_i="41962" xml_f="42114" txt_i="32296" txt_f="32448">]. The PHQ-9 has been found to be a valid and reliable instrument to measure the severity of depression in patients with different medical backgrounds [</offsets><xref ref-type="bibr" rid="B47"><offsets xml_i="42146" xml_f="42148" txt_i="32448" txt_f="32450">47</offsets></xref><offsets xml_i="42155" xml_f="42258" txt_i="32450" txt_f="32553">]. In an earlier study, the PHQ-9 was used successfully for the diagnosis of MDD in diabetic patients [</offsets><xref ref-type="bibr" rid="B85"><offsets xml_i="42290" xml_f="42292" txt_i="32553" txt_f="32555">85</offsets></xref><offsets xml_i="42299" xml_f="42301" txt_i="32555" txt_f="32557">].</offsets></p><p><offsets xml_i="42308" xml_f="42413" txt_i="32558" txt_f="32663">An improvement of more than five points on the PHQ-9 can be considered a clinically relevant difference [</offsets><xref ref-type="bibr" rid="B86"><offsets xml_i="42445" xml_f="42447" txt_i="32663" txt_f="32665">86</offsets></xref><offsets xml_i="42454" xml_f="42668" txt_i="32665" txt_f="32879">]. The PHQ-9 will be administered at baseline and during treatment at least every other week (before each appointment with the care manager). After treatment, the PHQ-9 will be administered every three months (3 (T</offsets><sub><offsets xml_i="42673" xml_f="42674" txt_i="32879" txt_f="32880">1</offsets></sub><offsets xml_i="42680" xml_f="42687" txt_i="32880" txt_f="32887">), 6 (T</offsets><sub><offsets xml_i="42692" xml_f="42693" txt_i="32887" txt_f="32888">2</offsets></sub><offsets xml_i="42699" xml_f="42706" txt_i="32888" txt_f="32895">), 9 (T</offsets><sub><offsets xml_i="42711" xml_f="42712" txt_i="32895" txt_f="32896">3</offsets></sub><offsets xml_i="42718" xml_f="42729" txt_i="32896" txt_f="32907">) and 12 (T</offsets><sub><offsets xml_i="42734" xml_f="42735" txt_i="32907" txt_f="32908">4</offsets></sub><offsets xml_i="42741" xml_f="42766" txt_i="32908" txt_f="32933">) months after baseline).</offsets></p></sec></sec><sec><title><offsets xml_i="42794" xml_f="42822" txt_i="32936" txt_f="32964">2. Secondary outcome measure</offsets></title><sec><title><offsets xml_i="42842" xml_f="42860" txt_i="32965" txt_f="32983">Cost-effectiveness</offsets></title><p><offsets xml_i="42871" xml_f="43249" txt_i="32984" txt_f="33362">In addition to the improvement of severity of symptoms, the cost-utility of collaborative care compared to CAU is assessed in this study. Therefore, an estimation of the direct medical costs and the costs due to production losses (productivity costs) is made. To estimate the costs the 'Trimbos/iMTA questionnaire for costs associated with psychiatric illness' (TiC-P) is used [</offsets><xref ref-type="bibr" rid="B87"><offsets xml_i="43281" xml_f="43283" txt_i="33362" txt_f="33364">87</offsets></xref><offsets xml_i="43290" xml_f="43291" txt_i="33364" txt_f="33365">,</offsets><xref ref-type="bibr" rid="B88"><offsets xml_i="43323" xml_f="43325" txt_i="33365" txt_f="33367">88</offsets></xref><offsets xml_i="43332" xml_f="43388" txt_i="33367" txt_f="33423">] Quality of life is assessed by the 'EuroQol' (EQ-5D) [</offsets><xref ref-type="bibr" rid="B89"><offsets xml_i="43420" xml_f="43422" txt_i="33423" txt_f="33425">89</offsets></xref><offsets xml_i="43429" xml_f="43503" txt_i="33425" txt_f="33499">] and the 'Medical Outcomes Study Short Form Health Survey â 36' (SF-36) [</offsets><xref ref-type="bibr" rid="B90"><offsets xml_i="43535" xml_f="43537" txt_i="33499" txt_f="33501">90</offsets></xref><offsets xml_i="43544" xml_f="43626" txt_i="33501" txt_f="33583">]. These are validated tools for measuring general health-related quality of life.</offsets></p><p><offsets xml_i="43633" xml_f="43867" txt_i="33584" txt_f="33818">The EQ-5D descriptive system consists of five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each with three levels (no problems, some problems, and extreme problems), thus defining 243 (3</offsets><sup><offsets xml_i="43872" xml_f="43873" txt_i="33818" txt_f="33819">5</offsets></sup><offsets xml_i="43879" xml_f="43904" txt_i="33819" txt_f="33844">) distinct health states.</offsets></p><p><offsets xml_i="43911" xml_f="44156" txt_i="33845" txt_f="34090">A recent study in the Netherlands measured and valuated the EQ-5D, resulting in the 'Dutch EQ-5D tariff', which is used to calculate utilities for EQ-5D health states for the cost-utility analyses of Dutch health care programmes and treatments [</offsets><xref ref-type="bibr" rid="B91"><offsets xml_i="44188" xml_f="44190" txt_i="34090" txt_f="34092">91</offsets></xref><offsets xml_i="44197" xml_f="44198" txt_i="34092" txt_f="34093">,</offsets><xref ref-type="bibr" rid="B92"><offsets xml_i="44230" xml_f="44232" txt_i="34093" txt_f="34095">92</offsets></xref><offsets xml_i="44239" xml_f="44240" txt_i="34095" txt_f="34096">]</offsets></p><p><offsets xml_i="44247" xml_f="44405" txt_i="34097" txt_f="34255">The SF-36 is a self-administered questionnaire, designed for use in clinical practice and research, health policy evaluations and general population surveys [</offsets><xref ref-type="bibr" rid="B90"><offsets xml_i="44437" xml_f="44439" txt_i="34255" txt_f="34257">90</offsets></xref><offsets xml_i="44446" xml_f="44911" txt_i="34257" txt_f="34722">]. It assesses eight health concepts: 1) limitations in physical activities due to health problems, 2) limitations in social activities due to physical or emotional problems, 3) limitations in usual role activities due to physical health problems, 4) bodily pain, 5) general mental health (psychological distress and well-being), 6) limitations in usual role activities due to emotional problems, 7) vitality (energy and fatigue), and 8) general health perceptions.</offsets></p><p><offsets xml_i="44918" xml_f="45262" txt_i="34723" txt_f="35067">The cost-utility will be evaluated by relating the difference in direct medical costs per patient, receiving either collaborative care or CAU, to the difference in terms of 'Quality Adjusted Life Years' (QALY) gained, which yields a cost per QALY estimate. Furthermore, we will also estimate the cost per QALY, including the productivity costs.</offsets></p></sec></sec><sec><title><offsets xml_i="45290" xml_f="45312" txt_i="35070" txt_f="35092">3. Key effect modifier</offsets></title><p><italic><offsets xml_i="45331" xml_f="45348" txt_i="35093" txt_f="35110">Physical illness </offsets></italic><offsets xml_i="45357" xml_f="45630" txt_i="35110" txt_f="35383">is considered to be the key effect modifier, and will be measured according to the CBS list, a questionnaire developed by the Central Bureau for Statistics (CBS) in the Netherlands. The CBS list contains 28 chronic conditions, ranging from DM type II to multiple sclerosis.</offsets></p></sec><sec><title><offsets xml_i="45652" xml_f="45703" txt_i="35385" txt_f="35436">4. Additional outcome measures and effect modifiers</offsets></title><p><italic><offsets xml_i="45722" xml_f="45742" txt_i="35437" txt_f="35457">Depressive symptoms </offsets></italic><offsets xml_i="45751" xml_f="45846" txt_i="35457" txt_f="35552">will also be assessed with the 'Inventory for Depressive Symptomatology-Self Report' (IDS-SR) [</offsets><xref ref-type="bibr" rid="B81"><offsets xml_i="45878" xml_f="45880" txt_i="35552" txt_f="35554">81</offsets></xref><offsets xml_i="45887" xml_f="45995" txt_i="35554" txt_f="35662">]. Remission (i.e. reduction in DSM-IV criteria below the threshold for a diagnosis of depressive disorder [</offsets><xref ref-type="bibr" rid="B68"><offsets xml_i="46027" xml_f="46029" txt_i="35662" txt_f="35664">68</offsets></xref><offsets xml_i="46036" xml_f="46166" txt_i="35664" txt_f="35794">]) of depressive symptoms will be measured according to the PHQ-9. Remission on the PHQ-9 is defined as a score of five or below [</offsets><xref ref-type="bibr" rid="B86"><offsets xml_i="46198" xml_f="46200" txt_i="35794" txt_f="35796">86</offsets></xref><offsets xml_i="46207" xml_f="46209" txt_i="35796" txt_f="35798">].</offsets></p><p><italic><offsets xml_i="46224" xml_f="46248" txt_i="35799" txt_f="35823">Somatoform presentation </offsets></italic><offsets xml_i="46257" xml_f="46504" txt_i="35823" txt_f="36070">will be assessed with five questionnaires. Firstly, presentation will be assessed as the number and intensity of functional somatic complaints a patient reports on the 'Bodily Complaints Questionnaire' ('Lichamelijke Klachten Vragenlijst' [LKV]) [</offsets><xref ref-type="bibr" rid="B93"><offsets xml_i="46536" xml_f="46538" txt_i="36070" txt_f="36072">93</offsets></xref><offsets xml_i="46545" xml_f="46672" txt_i="36072" txt_f="36199">]. Secondly, possible comorbid somatoform disorder will be assessed with the 'Screening for Somatoform Symptoms â 7' (SOMS-7) [</offsets><xref ref-type="bibr" rid="B94"><offsets xml_i="46704" xml_f="46706" txt_i="36199" txt_f="36201">94</offsets></xref><offsets xml_i="46713" xml_f="46786" txt_i="36201" txt_f="36274">]. Thirdly, hypochondria will be measured with the 'Whitley Index' (WI) [</offsets><xref ref-type="bibr" rid="B95"><offsets xml_i="46818" xml_f="46820" txt_i="36274" txt_f="36276">95</offsets></xref><offsets xml_i="46827" xml_f="46828" txt_i="36276" txt_f="36277">,</offsets><xref ref-type="bibr" rid="B96"><offsets xml_i="46860" xml_f="46862" txt_i="36277" txt_f="36279">96</offsets></xref><offsets xml_i="46869" xml_f="46977" txt_i="36279" txt_f="36387">]. Fourthly, health anxiety and illness behaviour will be measured with the 'Illness Attitude Scale' (IAS) [</offsets><xref ref-type="bibr" rid="B95"><offsets xml_i="47009" xml_f="47011" txt_i="36387" txt_f="36389">95</offsets></xref><offsets xml_i="47018" xml_f="47114" txt_i="36389" txt_f="36485">]. Finally, pain will be measured with one scale of the SF-36 and a visual analogue scale (VAS).</offsets></p><p><italic><offsets xml_i="47129" xml_f="47177" txt_i="36486" txt_f="36534">Associated symptoms of comorbid chronic illness </offsets></italic><offsets xml_i="47186" xml_f="47342" txt_i="36534" txt_f="36690">will be measured as fatigue, according to the Dutch version of the 'Multidimensional Fatigue Inventory' ('Multidimensionele Vermoeidheids Index' [MVI-20]) [</offsets><xref ref-type="bibr" rid="B97"><offsets xml_i="47374" xml_f="47376" txt_i="36690" txt_f="36692">97</offsets></xref><offsets xml_i="47383" xml_f="47384" txt_i="36692" txt_f="36693">,</offsets><xref ref-type="bibr" rid="B98"><offsets xml_i="47416" xml_f="47418" txt_i="36693" txt_f="36695">98</offsets></xref><offsets xml_i="47425" xml_f="47528" txt_i="36695" txt_f="36798">] and as disability with the 'World Health Organization-Disability Assessment Survey-II' (WHO-DAS-II) [</offsets><xref ref-type="bibr" rid="B99"><offsets xml_i="47560" xml_f="47562" txt_i="36798" txt_f="36800">99</offsets></xref><offsets xml_i="47569" xml_f="47571" txt_i="36800" txt_f="36802">].</offsets></p><p><italic><offsets xml_i="47586" xml_f="47610" txt_i="36803" txt_f="36827">Preference and adherence</offsets></italic><offsets xml_i="47619" xml_f="47820" txt_i="36827" txt_f="37028">. Preferences of the patient will be assessed according to the choices patients make in the intervention group. Patient and provider adherence will be assessed by means of a qualitative questionnaire [</offsets><xref ref-type="bibr" rid="B57"><offsets xml_i="47852" xml_f="47854" txt_i="37028" txt_f="37030">57</offsets></xref><offsets xml_i="47861" xml_f="47999" txt_i="37030" txt_f="37168">]. The working relationship between the patient and the care manager will be measured with the 'Helping Alliance Questionnaire' (HAQ-II) [</offsets><xref ref-type="bibr" rid="B100"><offsets xml_i="48032" xml_f="48035" txt_i="37168" txt_f="37171">100</offsets></xref><offsets xml_i="48042" xml_f="48088" txt_i="37171" txt_f="37217">], because the care manager will provide PST [</offsets><xref ref-type="bibr" rid="B101"><offsets xml_i="48121" xml_f="48124" txt_i="37217" txt_f="37220">101</offsets></xref><offsets xml_i="48131" xml_f="48279" txt_i="37220" txt_f="37368">]. The attitude of the care manager towards the treatment of depressive disorder will be measured with the Depression Attitude Questionnaire (DAQ) [</offsets><xref ref-type="bibr" rid="B102"><offsets xml_i="48312" xml_f="48315" txt_i="37368" txt_f="37371">102</offsets></xref><offsets xml_i="48322" xml_f="48323" txt_i="37371" txt_f="37372">,</offsets><xref ref-type="bibr" rid="B103"><offsets xml_i="48356" xml_f="48359" txt_i="37372" txt_f="37375">103</offsets></xref><offsets xml_i="48366" xml_f="48367" txt_i="37375" txt_f="37376">]</offsets></p><p><italic><offsets xml_i="48382" xml_f="48413" txt_i="37377" txt_f="37408">Life-events and social support </offsets></italic><offsets xml_i="48422" xml_f="48492" txt_i="37408" txt_f="37478">will be assessed according to the 'Social Readjustment Rating Scale' [</offsets><xref ref-type="bibr" rid="B104"><offsets xml_i="48525" xml_f="48528" txt_i="37478" txt_f="37481">104</offsets></xref><offsets xml_i="48535" xml_f="48616" txt_i="37481" txt_f="37562">] to indicate the amount of change in daily life, and by two items on the SF-36 [</offsets><xref ref-type="bibr" rid="B90"><offsets xml_i="48648" xml_f="48650" txt_i="37562" txt_f="37564">90</offsets></xref><offsets xml_i="48657" xml_f="48659" txt_i="37564" txt_f="37566">].</offsets></p><p><italic><offsets xml_i="48674" xml_f="48693" txt_i="37567" txt_f="37586">Personality traits </offsets></italic><offsets xml_i="48702" xml_f="48876" txt_i="37586" txt_f="37760">will be measured according to the neuroticism and extraversion scales of the 'NEO Five-Factor Inventory' (NEO-FFI), the abbreviated version of the NEO personality inventory [</offsets><xref ref-type="bibr" rid="B105"><offsets xml_i="48909" xml_f="48912" txt_i="37760" txt_f="37763">105</offsets></xref><offsets xml_i="48919" xml_f="48921" txt_i="37763" txt_f="37765">].</offsets></p><p><italic><offsets xml_i="48936" xml_f="48963" txt_i="37766" txt_f="37793">Treatment in the CAU group </offsets></italic><offsets xml_i="48972" xml_f="49211" txt_i="37793" txt_f="38032">will be assessed with the 'Scale assessing contacts between patients and practitioners' ('Contacten met doctors en andere behandelaars') and the 'Scale assessing medical utilization of health services' ('Vragenlijst medische consumptie') [</offsets><xref ref-type="bibr" rid="B57"><offsets xml_i="49243" xml_f="49245" txt_i="38032" txt_f="38034">57</offsets></xref><offsets xml_i="49252" xml_f="49332" txt_i="38034" txt_f="38114">]. Both questionnaires measure the consumption of (medical) care of the patient.</offsets></p></sec></sec><sec><title><offsets xml_i="49360" xml_f="49378" txt_i="38117" txt_f="38135">Power calculations</offsets></title><p><offsets xml_i="49389" xml_f="49890" txt_i="38136" txt_f="38637">In this study, the PHQ-9 will be used as the primary outcome measure. In order to detect a standardised difference of 0.5 standard deviation in the primary outcome measure (which can be considered as a clinically relevant difference), 2 Ã 63 patients are needed when two-sided testing and 80% power is assumed. Intention-to-treat analysis will be applied. Therefore, 126 patients will be needed. An improvement of more than five points on the PHQ-9 can be considered a clinically relevant difference [</offsets><xref ref-type="bibr" rid="B86"><offsets xml_i="49922" xml_f="49924" txt_i="38637" txt_f="38639">86</offsets></xref><offsets xml_i="49931" xml_f="49933" txt_i="38639" txt_f="38641">].</offsets></p></sec><sec><title><offsets xml_i="49955" xml_f="49963" txt_i="38643" txt_f="38651">Analyses</offsets></title><p><offsets xml_i="49974" xml_f="50438" txt_i="38652" txt_f="39116">A collaborative care model for the treatment of major depressive disorder in outpatients of a general hospital setting with DM, CVD, and COPD is more effective and more cost-effective than CAU, is the hypothesis underlying the present study. The primary outcome is the effectiveness in terms of the severity of the depressive symptoms, as measured by the PHQ-9. The secondary outcome is the cost-effectiveness, as measured with the TiC-P, the EQ-5D, and the SF-36.</offsets></p><sec><title><offsets xml_i="50454" xml_f="50470" txt_i="39117" txt_f="39133">a. Effectiveness</offsets></title><p><offsets xml_i="50481" xml_f="51351" txt_i="39134" txt_f="40004">Continuous outcome measures will be used to measure the effectiveness of the present intervention. A t-test with intention-to-treat analysis will be performed. When missing data arises, methods like 'last observation carried forward' (LOCF) or 'multiple imputation' will be used. The central effect modifier with regard to the effect of collaborative care is comorbid chronic illness. Furthermore, somatoform presentation, associated symptoms of comorbid chronic illness, preference and adherence, life-events and social support, and personality traits will be included in the analysis as potential effect modifiers. The effect size will be estimated by Chi-square analysis and described in Cohen's d. Possible confounders, such as age, gender, immigrant status, level of education, and treatment history, will be included as variables in logistical regression analysis.</offsets></p></sec><sec><title><offsets xml_i="51373" xml_f="51395" txt_i="40006" txt_f="40028">b. Economic evaluation</offsets></title><p><offsets xml_i="51406" xml_f="51938" txt_i="40029" txt_f="40561">The aim of the economic evaluation is to assess the cost-effectiveness of collaborative care for the treatment of depressive disorders in the general hospital setting. A cost-utility analysis (CUA) will be applied, the results of which will be expressed as cost per QALY. The economic evaluation will be undertaken from a societal perspective, so all relevant effects and costs due to resource utilisation within the health care system (direct medical costs) and costs due to production losses (productivity costs) will be included.</offsets></p><p><offsets xml_i="51945" xml_f="52631" txt_i="40562" txt_f="41248">Since the collaborative care intervention used in this study is new intervention, a unit price per session is not known yet. To determine a reference price, a detailed cost-price study will be performed. Therefore, we will perform measurements of time for face-to-face contacts as well as indirect time per contact (e.g. consultations of other specialists) for a total of 20 sessions. Furthermore, we will estimate overhead costs based on the information of the financial department of the hospital. This will result in an estimate of the actual costs per contact. The unit cost estimate per contact will be used as a reference price per contact for the collaborative care intervention.</offsets></p><p><offsets xml_i="52638" xml_f="52682" txt_i="41249" txt_f="41293">The TiC-P will be used to assess the costs [</offsets><xref ref-type="bibr" rid="B87"><offsets xml_i="52714" xml_f="52716" txt_i="41293" txt_f="41295">87</offsets></xref><offsets xml_i="52723" xml_f="52969" txt_i="41295" txt_f="41541">]. The TiC-P iscommonly applied in economic evaluations of treatments in mental health care. For instance, the TiC-P was recently used in a large naturalistic trial on the cost-utility of brief psychological treatment for depression and anxiety [</offsets><xref ref-type="bibr" rid="B88"><offsets xml_i="53001" xml_f="53003" txt_i="41541" txt_f="41543">88</offsets></xref><offsets xml_i="53010" xml_f="53012" txt_i="41543" txt_f="41545">].</offsets></p><p><offsets xml_i="53019" xml_f="53389" txt_i="41546" txt_f="41916">Calculating the total direct medical costs, the total number of medical contacts (outpatient visits, length of stay in hospital, use of medication, etc.) will be multiplied by unit costs of the corresponding health care services. Reference unit prices of health care services will be applied, and adjusted to the year of the study according to the consumer price index [</offsets><xref ref-type="bibr" rid="B106"><offsets xml_i="53422" xml_f="53425" txt_i="41916" txt_f="41919">106</offsets></xref><offsets xml_i="53432" xml_f="53434" txt_i="41919" txt_f="41921">].</offsets></p><p><offsets xml_i="53441" xml_f="53584" txt_i="41922" txt_f="42065">The second section of the TiC-P includes a short form of the Health and Labour questionnaire (HLQ) for collecting data on productivity losses [</offsets><xref ref-type="bibr" rid="B107"><offsets xml_i="53617" xml_f="53620" txt_i="42065" txt_f="42068">107</offsets></xref><offsets xml_i="53627" xml_f="53803" txt_i="42068" txt_f="42244">]. The Short-Form HLQ (SF-HLQ) consists of three modules that measure productivity losses: absence from work, reduced efficiency at work and difficulties with job performance [</offsets><xref ref-type="bibr" rid="B108"><offsets xml_i="53836" xml_f="53839" txt_i="42244" txt_f="42247">108</offsets></xref><offsets xml_i="53846" xml_f="54348" txt_i="42247" txt_f="42749">]. The number of days absent from work and the actual cost of hours missed at work due to health-related problems are valued according to the average value added per worker by age and gender per day and per hour, respectively. If respondents indicate that they have been absent for the entire recall period, data will be collected from the time when the period of long-term absence started. This additional information will be used to value the production losses according to the friction cost method [</offsets><xref ref-type="bibr" rid="B109"><offsets xml_i="54381" xml_f="54384" txt_i="42749" txt_f="42752">109</offsets></xref><offsets xml_i="54391" xml_f="54392" txt_i="42752" txt_f="42753">,</offsets><xref ref-type="bibr" rid="B110"><offsets xml_i="54425" xml_f="54428" txt_i="42753" txt_f="42756">110</offsets></xref><offsets xml_i="54435" xml_f="54666" txt_i="42756" txt_f="42987">]. The friction cost method takes into account the economic circumstances that limit the losses of productivity to society, which are related to the fact that a formerly unemployed person may replace a person who becomes disabled [</offsets><xref ref-type="bibr" rid="B109"><offsets xml_i="54699" xml_f="54702" txt_i="42987" txt_f="42990">109</offsets></xref><offsets xml_i="54709" xml_f="54711" txt_i="42990" txt_f="42992">].</offsets></p><p><offsets xml_i="54718" xml_f="55186" txt_i="42993" txt_f="43461">For the economic evaluation, the effects will be measured according to utility scores. In addition to the clinical outcome parameters, the utility scores will supply additional information about the impact of collaborative care on the treatment of MDD compared to the impact of CAU on the general health related quality of life. Furthermore, the results can be compared to a broad range of other health care interventions, also outside the field of mental health care.</offsets></p><p><offsets xml_i="55193" xml_f="55497" txt_i="43462" txt_f="43766">The cost-utility will be evaluated by relating the difference in direct medical costs per patient receiving collaborative care or CAU to the difference in terms of QALYs gained, which yields a cost per QALY estimate. Furthermore, we will also estimate the cost per QALY, including the productivity costs.</offsets></p><p><offsets xml_i="55504" xml_f="55640" txt_i="43767" txt_f="43903">In the case of missing data on costs and/or effects, and the additional uncertainty this introduces, we will use 'multiple imputation' [</offsets><xref ref-type="bibr" rid="B111"><offsets xml_i="55673" xml_f="55676" txt_i="43903" txt_f="43906">111</offsets></xref><offsets xml_i="55683" xml_f="55885" txt_i="43906" txt_f="44108">]. We will use the Monte Carlo Markov Chain (MCMC) approach to impute the missing values. The uncertainty will be assessed with bootstrapping, and the results will be presented in acceptability curves [</offsets><xref ref-type="bibr" rid="B112"><offsets xml_i="55918" xml_f="55921" txt_i="44108" txt_f="44111">112</offsets></xref><offsets xml_i="55928" xml_f="55930" txt_i="44111" txt_f="44113">].</offsets></p></sec></sec><sec><title><offsets xml_i="55958" xml_f="55981" txt_i="44116" txt_f="44139">Time-frame of the study</offsets></title><p><offsets xml_i="55992" xml_f="56224" txt_i="44140" txt_f="44372">The preparatory period will be 6 months. After approval has been received from the Medical Ethical Committee, the care managers are trained. The inclusion and intervention phase will take 22 months. The follow-up phases will be 3 (T</offsets><sub><offsets xml_i="56229" xml_f="56230" txt_i="44372" txt_f="44373">1</offsets></sub><offsets xml_i="56236" xml_f="56243" txt_i="44373" txt_f="44380">), 6 (T</offsets><sub><offsets xml_i="56248" xml_f="56249" txt_i="44380" txt_f="44381">2</offsets></sub><offsets xml_i="56255" xml_f="56262" txt_i="44381" txt_f="44388">), 9 (T</offsets><sub><offsets xml_i="56267" xml_f="56268" txt_i="44388" txt_f="44389">3</offsets></sub><offsets xml_i="56274" xml_f="56293" txt_i="44389" txt_f="44408">), and 12 months (T</offsets><sub><offsets xml_i="56298" xml_f="56299" txt_i="44408" txt_f="44409">4</offsets></sub><offsets xml_i="56305" xml_f="56447" txt_i="44409" txt_f="44551">) after inclusion. Data-analyses will take another 6 months, with interim reporting every year. The entire study period will last for 4 years.</offsets></p></sec><sec><title><offsets xml_i="56469" xml_f="56487" txt_i="44553" txt_f="44571">Ethical principles</offsets></title><p><offsets xml_i="56498" xml_f="56668" txt_i="44572" txt_f="44742">The study has been planned, and will be carried out in accordance with the principles laid down in the Helsinki declaration (Edinburgh, Scotland amendment, October 2000).</offsets></p><p><offsets xml_i="56675" xml_f="57197" txt_i="44743" txt_f="45265">Participation in the study is voluntarily. The patients will be informed in writing and verbally about the global features of the study, the possible benefits of participating in the experimental group, and the societal aspects of the study. The patients will be explicitly informed of the fact that they can withdraw their consent to participate at any time, without specification of any reasons, and with no negative consequences for their future treatment. Patients who wish to withdraw from the study will receive CAU.</offsets></p><p><offsets xml_i="57204" xml_f="57361" txt_i="45266" txt_f="45423">Informed consent will be obtained twice from the patients. First, prior to completion of the baseline questionnaire, and again before inclusion in the study.</offsets></p><p><offsets xml_i="57368" xml_f="57732" txt_i="45424" txt_f="45788">The names of the patients and other confidential information will be treated according to the medical confidentiality rules and patient data will be separated from patient names. The patients will be anonymous, because each participant will be identified in the database by a number and a code. The codes will only be available for the participating investigators.</offsets></p><p><offsets xml_i="57739" xml_f="58050" txt_i="45789" txt_f="46100">Furthermore, all study-related data will be stored on a protected Trimbos Institute server, access to which granted exclusively to the members of the research team. The investigators will be responsible for the administration of the study. The results of the surveys will not be disclosed to the hospital staff.</offsets></p><p><offsets xml_i="58057" xml_f="58154" txt_i="46101" txt_f="46198">The Medical Ethical Committee of the OLVG has approved of the study protocol (study no WO06-066).</offsets></p></sec></sec><sec><title><offsets xml_i="58182" xml_f="58192" txt_i="46201" txt_f="46211">Discussion</offsets></title><p><offsets xml_i="58203" xml_f="58985" txt_i="46212" txt_f="46994">There is a high prevalence of chronically ill patients suffering from depression, and interventions for the treatment of comorbid depression are urgently needed. Evidence for effective treatment does exist, but these are frequently not applied. The current trial is designed to implement evidence-based treatments for depression in the general hospital setting, and to test the hypothesis that these treatments are more effective and cost-effective than CAU. This is a pragmatic trial; hence, the objective of the trial is to assess the benefits of the treatment in routine clinical practice. The relationship between depressive symptoms and the course of several chronic illnesses suggests that this line of research may be of considerable importance in the field of public health.</offsets></p></sec><sec><title><offsets xml_i="59007" xml_f="59026" txt_i="46996" txt_f="47015">Competing interests</offsets></title><p><offsets xml_i="59037" xml_f="59097" txt_i="47016" txt_f="47076">The author(s) declare that they have no competing interests.</offsets></p></sec><sec><title><offsets xml_i="59119" xml_f="59141" txt_i="47078" txt_f="47100">Authors' contributions</offsets></title><p><offsets xml_i="59152" xml_f="59587" txt_i="47101" txt_f="47536">EKH and TBB will execute the trial and participate in the implementation. CMFC is principle investigator, conceived the study, and will assist with the implementation. LKR, HWJM, FR, and ATFB will assist with the implementation. As members of the research team, all the authors have contributed to the development of the protocol and the study design, read the manuscript, provided editorial comments and approved the final manuscript.</offsets></p></sec><sec><title><offsets xml_i="59609" xml_f="59632" txt_i="47538" txt_f="47561">Pre-publication history</offsets></title><p><offsets xml_i="59643" xml_f="59707" txt_i="47562" txt_f="47626">The pre-publication history for this paper can be accessed here:</offsets></p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1472-6963/7/28/prepub"></ext-link></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This research was funded by the Foundation Central Funds RVVZ (Reserves Formally Voluntary National Health Service insurances) in the Netherlands and the Onze Lieve Vrouwe Gasthuis in Amsterdam. We would also like to thank JÃ¼rgen UnÃ¼tzer, Diane Powers and Rita Haverkamp, connected to the IMPACT research group, for providing training and advice.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bijl</surname><given-names>RV</given-names></name><name><surname>Ravelli</surname><given-names>A</given-names></name><name><surname>van Zessen</surname><given-names>G</given-names></name></person-group><article-title>Prevalence of psychiatric disorder in the general population: results of The Netherlands Mental Health Survey and Incidence Study (NEMESIS)</article-title><source>Soc Psychiatry Psychiatr Epidemiol</source><year>1998</year><volume>33</volume><fpage>587</fpage><lpage>595</lpage><pub-id pub-id-type="pmid">9857791</pub-id><pub-id pub-id-type="doi">10.1007/s001270050098</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>CJ</given-names></name><name><surname>Lopez</surname><given-names>AD</given-names></name></person-group><article-title>Alternative projections of mortality and disability by cause 1990â2020: Global Burden of Disease Study</article-title><source>Lancet</source><year>1997</year><volume>349</volume><fpage>1498</fpage><lpage>1504</lpage><pub-id pub-id-type="pmid">9167458</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(96)07492-2</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mikkelsen</surname><given-names>RL</given-names></name><name><surname>Middelboe</surname><given-names>T</given-names></name><name><surname>Pisinger</surname><given-names>C</given-names></name><name><surname>Stage</surname><given-names>KB</given-names></name></person-group><article-title>Anxiety and depression in patients with chronic obstructive pulmonary disease (COPD). A review</article-title><source>Nord J Psychiatry</source><year>2004</year><volume>58</volume><fpage>65</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">14985157</pub-id><pub-id pub-id-type="doi">10.1080/08039480310000824</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cigognini</surname><given-names>MA</given-names></name><name><surname>Furlanetto</surname><given-names>LM</given-names></name></person-group><article-title>Diagnosis and pharmacological treatment of depressive disorders in a general hospital</article-title><source>Rev Bras Psiquiatr</source><year>2006</year><volume>28</volume><fpage>97</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">16810391</pub-id><pub-id pub-id-type="doi">10.1590/S1516-44462006000200005</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peveler</surname><given-names>R</given-names></name><name><surname>Carson</surname><given-names>A</given-names></name><name><surname>Rodin</surname><given-names>G</given-names></name></person-group><article-title>Depression in medical patients</article-title><source>BMJ</source><year>2002</year><volume>325</volume><fpage>149</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">12130614</pub-id><pub-id pub-id-type="doi">10.1136/bmj.325.7356.149</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Licht-Strunk</surname><given-names>E</given-names></name><name><surname>van der Kooij</surname><given-names>KG</given-names></name><name><surname>van Schaik</surname><given-names>DJ</given-names></name><name><surname>van Marwijk</surname><given-names>HW</given-names></name><name><surname>van Hout</surname><given-names>HP</given-names></name><name><surname>de Haan</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Prevalence of depression in older patients consulting their general practitioner in The Netherlands</article-title><source>Int J Geriatr Psychiatry</source><year>2005</year><volume>20</volume><fpage>1013</fpage><lpage>1019</lpage><pub-id pub-id-type="pmid">16250082</pub-id><pub-id pub-id-type="doi">10.1002/gps.1391</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Al Windi</surname><given-names>A</given-names></name></person-group><article-title>Depression in general practice</article-title><source>Nord J Psychiatry</source><year>2005</year><volume>59</volume><fpage>272</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">16195131</pub-id><pub-id pub-id-type="doi">10.1080/08039480500227733</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martucci</surname><given-names>M</given-names></name><name><surname>Balestrieri</surname><given-names>M</given-names></name><name><surname>Bisoffi</surname><given-names>G</given-names></name><name><surname>Bonizzato</surname><given-names>P</given-names></name><name><surname>Covre</surname><given-names>MG</given-names></name><name><surname>Cunico</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Evaluating psychiatric morbidity in a general hospital: a two-phase epidemiological survey</article-title><source>Psychol Med</source><year>1999</year><volume>29</volume><fpage>823</fpage><lpage>832</lpage><pub-id pub-id-type="pmid">10473309</pub-id><pub-id pub-id-type="doi">10.1017/S0033291799008491</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nutting</surname><given-names>PA</given-names></name><name><surname>Rost</surname><given-names>K</given-names></name><name><surname>Smith</surname><given-names>J</given-names></name><name><surname>Werner</surname><given-names>JJ</given-names></name><name><surname>Elliot</surname><given-names>C</given-names></name></person-group><article-title>Competing demands from physical problems: effect on initiating and completing depression care over 6 months</article-title><source>Arch Fam Med</source><year>2000</year><volume>9</volume><fpage>1059</fpage><lpage>1064</lpage><pub-id pub-id-type="pmid">11115208</pub-id><pub-id pub-id-type="doi">10.1001/archfami.9.10.1059</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goldney</surname><given-names>RD</given-names></name><name><surname>Phillips</surname><given-names>PJ</given-names></name><name><surname>Fisher</surname><given-names>LJ</given-names></name><name><surname>Wilson</surname><given-names>DH</given-names></name></person-group><article-title>Diabetes, depression, and quality of life: a population study</article-title><source>Diabetes Care</source><year>2004</year><volume>27</volume><fpage>1066</fpage><lpage>1070</lpage><pub-id pub-id-type="pmid">15111522</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Panzarino</surname><given-names>PJ</given-names><suffix>Jr</suffix></name></person-group><article-title>The costs of depression: direct and indirect; treatment versus nontreatment</article-title><source>J Clin Psychiatry</source><year>1998</year><volume>59</volume><fpage>11</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">9881536</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ciechanowski</surname><given-names>PS</given-names></name><name><surname>Katon</surname><given-names>WJ</given-names></name><name><surname>Russo</surname><given-names>JE</given-names></name></person-group><article-title>Depression and diabetes: impact of depressive symptoms on adherence, function, and costs</article-title><source>Arch Intern Med</source><year>2000</year><volume>160</volume><fpage>3278</fpage><lpage>3285</lpage><pub-id pub-id-type="pmid">11088090</pub-id><pub-id pub-id-type="doi">10.1001/archinte.160.21.3278</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goldney</surname><given-names>RD</given-names></name><name><surname>Ruffin</surname><given-names>R</given-names></name><name><surname>Fisher</surname><given-names>LJ</given-names></name><name><surname>Wilson</surname><given-names>DH</given-names></name></person-group><article-title>Asthma symptoms associated with depression and lower quality of life: a population survey</article-title><source>Med J Aust</source><year>2003</year><volume>178</volume><fpage>437</fpage><lpage>441</lpage><pub-id pub-id-type="pmid">12720509</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Afari</surname><given-names>N</given-names></name><name><surname>Schmaling</surname><given-names>KB</given-names></name><name><surname>Barnhart</surname><given-names>S</given-names></name><name><surname>Buchwald</surname><given-names>D</given-names></name></person-group><article-title>Psychiatric Comorbidity and Functional Status in Adult Patients with Asthma</article-title><source>Journal of Clinical Psychology in Medical Settings</source><year>2001</year><volume>8</volume><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1023/A:1011912712262</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cully</surname><given-names>JA</given-names></name><name><surname>Graham</surname><given-names>DP</given-names></name><name><surname>Stanley</surname><given-names>MA</given-names></name><name><surname>Ferguson</surname><given-names>CJ</given-names></name><name><surname>Sharafkhaneh</surname><given-names>A</given-names></name><name><surname>Souchek</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Quality of life in patients with chronic obstructive pulmonary disease and comorbid anxiety or depression</article-title><source>Psychosomatics</source><year>2006</year><volume>47</volume><fpage>312</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">16844889</pub-id><pub-id pub-id-type="doi">10.1176/appi.psy.47.4.312</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gehi</surname><given-names>A</given-names></name><name><surname>Haas</surname><given-names>D</given-names></name><name><surname>Pipkin</surname><given-names>S</given-names></name><name><surname>Whooley</surname><given-names>MA</given-names></name></person-group><article-title>Depression and medication adherence in outpatients with coronary heart disease: findings from the Heart and Soul Study</article-title><source>Arch Intern Med</source><year>2005</year><volume>165</volume><fpage>2508</fpage><lpage>2513</lpage><pub-id pub-id-type="pmid">16314548</pub-id><pub-id pub-id-type="doi">10.1001/archinte.165.21.2508</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>DiMatteo</surname><given-names>MR</given-names></name><name><surname>Lepper</surname><given-names>HS</given-names></name><name><surname>Croghan</surname><given-names>TW</given-names></name></person-group><article-title>Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence</article-title><source>Arch Intern Med</source><year>2000</year><volume>160</volume><fpage>2101</fpage><lpage>2107</lpage><pub-id pub-id-type="pmid">10904452</pub-id><pub-id pub-id-type="doi">10.1001/archinte.160.14.2101</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katon</surname><given-names>WJ</given-names></name></person-group><article-title>Clinical and health services relationships between major depression, depressive symptoms, and general medical illness</article-title><source>Biol Psychiatry</source><year>2003</year><volume>54</volume><fpage>216</fpage><lpage>226</lpage><pub-id pub-id-type="pmid">12893098</pub-id><pub-id pub-id-type="doi">10.1016/S0006-3223(03)00273-7</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knol</surname><given-names>MJ</given-names></name><name><surname>Twisk</surname><given-names>JW</given-names></name><name><surname>Beekman</surname><given-names>AT</given-names></name><name><surname>Heine</surname><given-names>RJ</given-names></name><name><surname>Snoek</surname><given-names>FJ</given-names></name><name><surname>Pouwer</surname><given-names>F</given-names></name></person-group><article-title>Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis</article-title><source>Diabetologia</source><year>2006</year><volume>49</volume><fpage>837</fpage><lpage>845</lpage><pub-id pub-id-type="pmid">16520921</pub-id><pub-id pub-id-type="doi">10.1007/s00125-006-0159-x</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Groot</surname><given-names>M</given-names></name><name><surname>Anderson</surname><given-names>R</given-names></name><name><surname>Freedland</surname><given-names>KE</given-names></name><name><surname>Clouse</surname><given-names>RE</given-names></name><name><surname>Lustman</surname><given-names>PJ</given-names></name></person-group><article-title>Association of depression and diabetes complications: a meta-analysis</article-title><source>Psychosom Med</source><year>2001</year><volume>63</volume><fpage>619</fpage><lpage>630</lpage><pub-id pub-id-type="pmid">11485116</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosenthal</surname><given-names>MJ</given-names></name><name><surname>Fajardo</surname><given-names>M</given-names></name><name><surname>Gilmore</surname><given-names>S</given-names></name><name><surname>Morley</surname><given-names>JE</given-names></name><name><surname>Naliboff</surname><given-names>BD</given-names></name></person-group><article-title>Hospitalization and mortality of diabetes in older adults. A 3-year prospective study</article-title><source>Diabetes Care</source><year>1998</year><volume>21</volume><fpage>231</fpage><lpage>235</lpage><pub-id pub-id-type="pmid">9539987</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Norris</surname><given-names>SL</given-names></name><name><surname>Gregg</surname><given-names>EW</given-names></name><name><surname>Cheng</surname><given-names>YJ</given-names></name><name><surname>Beckles</surname><given-names>G</given-names></name><name><surname>Kahn</surname><given-names>HS</given-names></name></person-group><article-title>Depressive symptoms and mortality among persons with and without diabetes</article-title><source>Am J Epidemiol</source><year>2005</year><volume>161</volume><fpage>652</fpage><lpage>660</lpage><pub-id pub-id-type="pmid">15781954</pub-id><pub-id pub-id-type="doi">10.1093/aje/kwi089</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barth</surname><given-names>J</given-names></name><name><surname>Schumacher</surname><given-names>M</given-names></name><name><surname>Herrmann-Lingen</surname><given-names>C</given-names></name></person-group><article-title>Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis</article-title><source>Psychosom Med</source><year>2004</year><volume>66</volume><fpage>802</fpage><lpage>813</lpage><pub-id pub-id-type="pmid">15564343</pub-id><pub-id pub-id-type="doi">10.1097/01.psy.0000146332.53619.b2</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Melle</surname><given-names>JP</given-names></name><name><surname>de Jonge</surname><given-names>P</given-names></name><name><surname>Spijkerman</surname><given-names>TA</given-names></name><name><surname>Tijssen</surname><given-names>JG</given-names></name><name><surname>Ormel</surname><given-names>J</given-names></name><name><surname>van Veldhuisen</surname><given-names>DJ</given-names></name><etal></etal></person-group><article-title>Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis</article-title><source>Psychosom Med</source><year>2004</year><volume>66</volume><fpage>814</fpage><lpage>822</lpage><pub-id pub-id-type="pmid">15564344</pub-id><pub-id pub-id-type="doi">10.1097/01.psy.0000146294.82810.9c</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koopmans</surname><given-names>GT</given-names></name><name><surname>Donker</surname><given-names>MC</given-names></name><name><surname>Rutten</surname><given-names>FH</given-names></name></person-group><article-title>Common mental disorders and use of general health services: a review of the literature on population-based studies</article-title><source>Acta Psychiatr Scand</source><year>2005</year><volume>111</volume><fpage>341</fpage><lpage>350</lpage><pub-id pub-id-type="pmid">15819727</pub-id><pub-id pub-id-type="doi">10.1111/j.1600-0447.2005.00496.x</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katon</surname><given-names>WJ</given-names></name><name><surname>Lin</surname><given-names>E</given-names></name><name><surname>Russo</surname><given-names>J</given-names></name><name><surname>Unutzer</surname><given-names>J</given-names></name></person-group><article-title>Increased medical costs of a population-based sample of depressed elderly patients</article-title><source>Arch Gen Psychiatry</source><year>2003</year><volume>60</volume><fpage>897</fpage><lpage>903</lpage><pub-id pub-id-type="pmid">12963671</pub-id><pub-id pub-id-type="doi">10.1001/archpsyc.60.9.897</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jonsson</surname><given-names>B</given-names></name><name><surname>Bebbington</surname><given-names>PE</given-names></name></person-group><article-title>What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment</article-title><source>Br J Psychiatry</source><year>1994</year><volume>164</volume><fpage>665</fpage><lpage>673</lpage><pub-id pub-id-type="pmid">7921718</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Treisman</surname><given-names>GJ</given-names></name><name><surname>Angelino</surname><given-names>AF</given-names></name><name><surname>Hutton</surname><given-names>HE</given-names></name></person-group><article-title>Psychiatric issues in the management of patients with HIV infection</article-title><source>JAMA</source><year>2001</year><volume>286</volume><fpage>2857</fpage><lpage>2864</lpage><pub-id pub-id-type="pmid">11735762</pub-id><pub-id pub-id-type="doi">10.1001/jama.286.22.2857</pub-id></citation></ref><ref id="B29"><citation citation-type="book"><person-group person-group-type="author"><collab>CBO, Trimbos-instituut</collab></person-group><source>Multidisciplinary Guideline Depressive disorder [Multidisciplinaire Richtlijn Depressie In Dutch]</source><year>2005</year><publisher-name>Utrecht: Trimbos-instituut</publisher-name></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stockton</surname><given-names>P</given-names></name><name><surname>Gonzales</surname><given-names>JJ</given-names></name><name><surname>Stern</surname><given-names>NP</given-names></name><name><surname>Epstein</surname><given-names>SA</given-names></name></person-group><article-title>Treatment patterns and outcomes of depressed medically ill and non-medically ill patients in community psychiatric practice</article-title><source>Gen Hosp Psychiatry</source><year>2004</year><volume>26</volume><fpage>2</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">14757295</pub-id><pub-id pub-id-type="doi">10.1016/S0163-8343(03)00094-X</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harpole</surname><given-names>LH</given-names></name><name><surname>Williams</surname><given-names>JW</given-names><suffix>Jr</suffix></name><name><surname>Olsen</surname><given-names>MK</given-names></name><name><surname>Stechuchak</surname><given-names>KM</given-names></name><name><surname>Oddone</surname><given-names>E</given-names></name><name><surname>Callahan</surname><given-names>CM</given-names></name><etal></etal></person-group><article-title>Improving depression outcomes in older adults with comorbid medical illness</article-title><source>Gen Hosp Psychiatry</source><year>2005</year><volume>27</volume><fpage>4</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">15694213</pub-id><pub-id pub-id-type="doi">10.1016/j.genhosppsych.2004.09.004</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rush</surname><given-names>AJ</given-names></name></person-group><article-title>Using what we know to better understand and treat depression</article-title><source>The journal of the california alliance for the mentally ill</source><year>1998</year><volume>9</volume><fpage>9</fpage><lpage>11</lpage></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hyman</surname><given-names>SE</given-names></name></person-group><article-title>Why is clinical depression so important?</article-title><source>The journal of the california alliance for the mentally ill</source><year>1998</year><volume>9</volume><fpage>11</fpage><lpage>13</lpage></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>GE</given-names></name></person-group><article-title>Social and economic burden of mood disorders</article-title><source>Biol Psychiatry</source><year>2003</year><volume>54</volume><fpage>208</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">12893097</pub-id><pub-id pub-id-type="doi">10.1016/S0006-3223(03)00420-7</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kathol</surname><given-names>RG</given-names></name><name><surname>Harsch</surname><given-names>HH</given-names></name><name><surname>Hall</surname><given-names>RC</given-names></name><name><surname>Shakespeare</surname><given-names>A</given-names></name><name><surname>Cowart</surname><given-names>T</given-names></name></person-group><article-title>Categorization of types of medical/psychiatry units based on level of acuity</article-title><source>Psychosomatics</source><year>1992</year><volume>33</volume><fpage>376</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">1461963</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kishi</surname><given-names>Y</given-names></name><name><surname>Kathol</surname><given-names>RG</given-names></name></person-group><article-title>Integrating medical and psychiatric treatment in an inpatient medical setting. The type IV program</article-title><source>Psychosomatics</source><year>1999</year><volume>40</volume><fpage>345</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">10402882</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neumeyer-Gromen</surname><given-names>A</given-names></name><name><surname>Lampert</surname><given-names>T</given-names></name><name><surname>Stark</surname><given-names>K</given-names></name><name><surname>Kallischnigg</surname><given-names>G</given-names></name></person-group><article-title>Disease management programs for depression: a systematic review and meta-analysis of randomized controlled trials</article-title><source>Med Care</source><year>2004</year><volume>42</volume><fpage>1211</fpage><lpage>1221</lpage><pub-id pub-id-type="pmid">15550801</pub-id><pub-id pub-id-type="doi">10.1097/00005650-200412000-00008</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katon</surname><given-names>W</given-names></name><name><surname>Russo</surname><given-names>J</given-names></name><name><surname>Von Korff</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>E</given-names></name><name><surname>Simon</surname><given-names>G</given-names></name><name><surname>Bush</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Long-term effects of a collaborative care intervention in persistently depressed primary care patients</article-title><source>J Gen Intern Med</source><year>2002</year><volume>17</volume><fpage>741</fpage><lpage>748</lpage><pub-id pub-id-type="pmid">12390549</pub-id><pub-id pub-id-type="doi">10.1046/j.1525-1497.2002.11051.x</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rost</surname><given-names>K</given-names></name><name><surname>Pyne</surname><given-names>JM</given-names></name><name><surname>Dickinson</surname><given-names>LM</given-names></name><name><surname>LoSasso</surname><given-names>AT</given-names></name></person-group><article-title>Cost-effectiveness of enhancing primary care depression management on an ongoing basis</article-title><source>Ann Fam Med</source><year>2005</year><volume>3</volume><fpage>7</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">15671185</pub-id><pub-id pub-id-type="doi">10.1370/afm.256</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Unutzer</surname><given-names>J</given-names></name><name><surname>Katon</surname><given-names>W</given-names></name><name><surname>Callahan</surname><given-names>CM</given-names></name><name><surname>Williams</surname><given-names>JW</given-names><suffix>Jr</suffix></name><name><surname>Hunkeler</surname><given-names>E</given-names></name><name><surname>Harpole</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial</article-title><source>JAMA</source><year>2002</year><volume>288</volume><fpage>2836</fpage><lpage>2845</lpage><pub-id pub-id-type="pmid">12472325</pub-id><pub-id pub-id-type="doi">10.1001/jama.288.22.2836</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katon</surname><given-names>W</given-names></name><name><surname>Unutzer</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>MY</given-names></name><name><surname>Williams</surname><given-names>JW</given-names><suffix>Jr</suffix></name><name><surname>Schoenbaum</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>EH</given-names></name><etal></etal></person-group><article-title>Cost-effectiveness and net benefit of enhanced treatment of depression for older adults with diabetes and depression</article-title><source>Diabetes Care</source><year>2006</year><volume>29</volume><fpage>265</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">16443871</pub-id><pub-id pub-id-type="doi">10.2337/diacare.29.02.06.dc05-1572</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lustman</surname><given-names>PJ</given-names></name><name><surname>Griffith</surname><given-names>LS</given-names></name><name><surname>Clouse</surname><given-names>RE</given-names></name></person-group><article-title>Depression in Adults with Diabetes</article-title><source>Semin Clin Neuropsychiatry</source><year>1997</year><volume>2</volume><fpage>15</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">10320439</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>RJ</given-names></name><name><surname>Freedland</surname><given-names>KE</given-names></name><name><surname>Clouse</surname><given-names>RE</given-names></name><name><surname>Lustman</surname><given-names>PJ</given-names></name></person-group><article-title>The prevalence of comorbid depression in adults with diabetes: a meta-analysis</article-title><source>Diabetes Care</source><year>2001</year><volume>24</volume><fpage>1069</fpage><lpage>1078</lpage><pub-id pub-id-type="pmid">11375373</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Whooley</surname><given-names>MA</given-names></name></person-group><article-title>Depression and cardiovascular disease: healing the broken-hearted</article-title><source>JAMA</source><year>2006</year><volume>295</volume><fpage>2874</fpage><lpage>2881</lpage><pub-id pub-id-type="pmid">16804154</pub-id><pub-id pub-id-type="doi">10.1001/jama.295.24.2874</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Di Marco</surname><given-names>F</given-names></name><name><surname>Verga</surname><given-names>M</given-names></name><name><surname>Reggente</surname><given-names>M</given-names></name><name><surname>Maria</surname><given-names>CF</given-names></name><name><surname>Santus</surname><given-names>P</given-names></name><name><surname>Blasi</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Anxiety and depression in COPD patients: The roles of gender and disease severity</article-title><source>Respir Med</source><year>2006</year><volume>100</volume><fpage>1767</fpage><lpage>1774</lpage><pub-id pub-id-type="pmid">16531031</pub-id><pub-id pub-id-type="doi">10.1016/j.rmed.2006.01.026</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ciesla</surname><given-names>JA</given-names></name><name><surname>Roberts</surname><given-names>JE</given-names></name></person-group><article-title>Meta-analysis of the relationship between HIV infection and risk for depressive disorders</article-title><source>Am J Psychiatry</source><year>2001</year><volume>158</volume><fpage>725</fpage><lpage>730</lpage><pub-id pub-id-type="pmid">11329393</pub-id><pub-id pub-id-type="doi">10.1176/appi.ajp.158.5.725</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kroenke</surname><given-names>K</given-names></name><name><surname>Spitzer</surname><given-names>RL</given-names></name><name><surname>Williams</surname><given-names>JB</given-names></name></person-group><article-title>The PHQ-9: validity of a brief depression severity measure</article-title><source>J Gen Intern Med</source><year>2001</year><volume>16</volume><fpage>606</fpage><lpage>613</lpage><pub-id pub-id-type="pmid">11556941</pub-id><pub-id pub-id-type="doi">10.1046/j.1525-1497.2001.016009606.x</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sheehan</surname><given-names>DV</given-names></name><name><surname>Lecrubier</surname><given-names>Y</given-names></name><name><surname>Sheehan</surname><given-names>KH</given-names></name><name><surname>Amorim</surname><given-names>P</given-names></name><name><surname>Janavs</surname><given-names>J</given-names></name><name><surname>Weiller</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10</article-title><source>J Clin Psychiatry</source><year>1998</year><volume>59</volume><fpage>22</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">9881538</pub-id></citation></ref><ref id="B49"><citation citation-type="book"><person-group person-group-type="author"><name><surname>van Vliet</surname><given-names>IM</given-names></name><name><surname>Leroy</surname><given-names>H</given-names></name><name><surname>van Megen</surname><given-names>HJM</given-names></name></person-group><source>De MINI-Internationaal neuropsychiatrisch interview: een kort gestructureerd diagnostisch interview voor DSM-IV en ICD-10 psychiatrische stoornissen</source><year>2000</year><publisher-name>Leiden: LUMC</publisher-name></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katon</surname><given-names>W</given-names></name><name><surname>Robinson</surname><given-names>P</given-names></name><name><surname>Von Korff</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>E</given-names></name><name><surname>Bush</surname><given-names>T</given-names></name><name><surname>Ludman</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>A multifaceted intervention to improve treatment of depression in primary care</article-title><source>Arch Gen Psychiatry</source><year>1996</year><volume>53</volume><fpage>924</fpage><lpage>932</lpage><pub-id pub-id-type="pmid">8857869</pub-id></citation></ref><ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katon</surname><given-names>W</given-names></name><name><surname>Von Korff</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>E</given-names></name><name><surname>Simon</surname><given-names>G</given-names></name><name><surname>Walker</surname><given-names>E</given-names></name><name><surname>Unutzer</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Stepped collaborative care for primary care patients with persistent symptoms of depression: a randomized trial</article-title><source>Arch Gen Psychiatry</source><year>1999</year><volume>56</volume><fpage>1109</fpage><lpage>1115</lpage><pub-id pub-id-type="pmid">10591288</pub-id><pub-id pub-id-type="doi">10.1001/archpsyc.56.12.1109</pub-id></citation></ref><ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katon</surname><given-names>W</given-names></name><name><surname>Von Korff</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>E</given-names></name><name><surname>Walker</surname><given-names>E</given-names></name><name><surname>Simon</surname><given-names>GE</given-names></name><name><surname>Bush</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Collaborative management to achieve treatment guidelines. Impact on depression in primary care</article-title><source>JAMA</source><year>1995</year><volume>273</volume><fpage>1026</fpage><lpage>1031</lpage><pub-id pub-id-type="pmid">7897786</pub-id><pub-id pub-id-type="doi">10.1001/jama.273.13.1026</pub-id></citation></ref><ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Unutzer</surname><given-names>J</given-names></name><name><surname>Katon</surname><given-names>W</given-names></name><name><surname>Williams</surname><given-names>JW</given-names><suffix>Jr</suffix></name><name><surname>Callahan</surname><given-names>CM</given-names></name><name><surname>Harpole</surname><given-names>L</given-names></name><name><surname>Hunkeler</surname><given-names>EM</given-names></name><etal></etal></person-group><article-title>Improving primary care for depression in late life: the design of a multicenter randomized trial</article-title><source>Med Care</source><year>2001</year><volume>39</volume><fpage>785</fpage><lpage>799</lpage><pub-id pub-id-type="pmid">11468498</pub-id><pub-id pub-id-type="doi">10.1097/00005650-200108000-00005</pub-id></citation></ref><ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meeuwissen</surname><given-names>JAC</given-names></name><name><surname>Doncker</surname><given-names>MCH</given-names></name></person-group><article-title>Minder is meer. Stepped care in de geestelijke gezondheidszorg</article-title><source>Maandblad Geestelijke Volksgezondheid</source><year>2004</year><volume>59</volume><fpage>904</fpage><lpage>915</lpage></citation></ref><ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van der Feltz-Cornelis</surname><given-names>CM</given-names></name><name><surname>van Oppen</surname><given-names>P</given-names></name><name><surname>Ader</surname><given-names>HJ</given-names></name><name><surname>van Dyck</surname><given-names>R</given-names></name></person-group><article-title>Randomised controlled trial of a collaborative care model with psychiatric consultation for persistent medically unexplained symptoms in general practice</article-title><source>Psychother Psychosom</source><year>2006</year><volume>75</volume><fpage>282</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">16899964</pub-id><pub-id pub-id-type="doi">10.1159/000093949</pub-id></citation></ref><ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trivedi</surname><given-names>MH</given-names></name><name><surname>Rush</surname><given-names>AJ</given-names></name><name><surname>Crismon</surname><given-names>ML</given-names></name><name><surname>Kashner</surname><given-names>TM</given-names></name><name><surname>Toprac</surname><given-names>MG</given-names></name><name><surname>Carmody</surname><given-names>TJ</given-names></name><etal></etal></person-group><article-title>Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project</article-title><source>Arch Gen Psychiatry</source><year>2004</year><volume>61</volume><fpage>669</fpage><lpage>680</lpage><pub-id pub-id-type="pmid">15237079</pub-id><pub-id pub-id-type="doi">10.1001/archpsyc.61.7.669</pub-id></citation></ref><ref id="B57"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Van der Feltz-Cornelis</surname><given-names>CM</given-names></name></person-group><source>Psychiatric consultation for patients with somatoform disorder in general practice</source><year>2002</year><publisher-name>VU Amsterdam</publisher-name></citation></ref><ref id="B58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weilburg</surname><given-names>JB</given-names></name><name><surname>O'Leary</surname><given-names>KM</given-names></name><name><surname>Meigs</surname><given-names>JB</given-names></name><name><surname>Hennen</surname><given-names>J</given-names></name><name><surname>Stafford</surname><given-names>RS</given-names></name></person-group><article-title>Evaluation of the adequacy of outpatient antidepressant treatment</article-title><source>Psychiatr Serv</source><year>2003</year><volume>54</volume><fpage>1233</fpage><lpage>1239</lpage><pub-id pub-id-type="pmid">12954939</pub-id><pub-id pub-id-type="doi">10.1176/appi.ps.54.9.1233</pub-id></citation></ref><ref id="B59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beliles</surname><given-names>K</given-names></name><name><surname>Stoudemire</surname><given-names>A</given-names></name></person-group><article-title>Psychopharmacologic treatment of depression in the medically ill</article-title><source>Psychosomatics</source><year>1998</year><volume>39</volume><fpage>S2</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">9664784</pub-id></citation></ref><ref id="B60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lowe</surname><given-names>B</given-names></name><name><surname>Schenkel</surname><given-names>I</given-names></name><name><surname>Bair</surname><given-names>MJ</given-names></name><name><surname>Gobel</surname><given-names>C</given-names></name></person-group><article-title>Efficacy, predictors of therapy response, and safety of sertraline in routine clinical practice: prospective, open-label, non-interventional postmarketing surveillance study in 1878 patients</article-title><source>J Affect Disord</source><year>2005</year><volume>87</volume><fpage>271</fpage><lpage>279</lpage><pub-id pub-id-type="pmid">15979151</pub-id><pub-id pub-id-type="doi">10.1016/j.jad.2005.05.005</pub-id></citation></ref><ref id="B61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Musselman</surname><given-names>DL</given-names></name><name><surname>Betan</surname><given-names>E</given-names></name><name><surname>Larsen</surname><given-names>H</given-names></name><name><surname>Phillips</surname><given-names>LS</given-names></name></person-group><article-title>Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment</article-title><source>Biol Psychiatry</source><year>2003</year><volume>54</volume><fpage>317</fpage><lpage>329</lpage><pub-id pub-id-type="pmid">12893107</pub-id><pub-id pub-id-type="doi">10.1016/S0006-3223(03)00569-9</pub-id></citation></ref><ref id="B62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fava</surname><given-names>M</given-names></name><name><surname>Mallinckrodt</surname><given-names>CH</given-names></name><name><surname>Detke</surname><given-names>MJ</given-names></name><name><surname>Watkin</surname><given-names>JG</given-names></name><name><surname>Wohlreich</surname><given-names>MM</given-names></name></person-group><article-title>The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?</article-title><source>J Clin Psychiatry</source><year>2004</year><volume>65</volume><fpage>521</fpage><lpage>530</lpage><pub-id pub-id-type="pmid">15119915</pub-id></citation></ref><ref id="B63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>D'Zurilla</surname><given-names>TJ</given-names></name><name><surname>Goldfried</surname><given-names>MR</given-names></name></person-group><article-title>Problem solving and behavior modification</article-title><source>J Abnorm Psychol</source><year>1971</year><volume>78</volume><fpage>107</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">4938262</pub-id><pub-id pub-id-type="doi">10.1037/h0031360</pub-id></citation></ref><ref id="B64"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Hawton</surname><given-names>K</given-names></name><name><surname>Kirk</surname><given-names>J</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Hawton K, Salkovskis P, Kirk K, Clark D</surname></name></person-group><article-title>Problem-solving</article-title><source>Cognitive behaviour therapy for psychiatric problems</source><year>1989</year><publisher-name>Oxford: Oxford University Press</publisher-name><fpage>406</fpage><lpage>426</lpage></citation></ref><ref id="B65"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mynors-Wallis</surname><given-names>L</given-names></name><name><surname>Davies</surname><given-names>I</given-names></name><name><surname>Gray</surname><given-names>A</given-names></name><name><surname>Barbour</surname><given-names>F</given-names></name><name><surname>Gath</surname><given-names>D</given-names></name></person-group><article-title>A randomised controlled trial and cost analysis of problem-solving treatment for emotional disorders given by community nurses in primary care</article-title><source>Br J Psychiatry</source><year>1997</year><volume>170</volume><fpage>113</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">9093498</pub-id></citation></ref><ref id="B66"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mynors-Wallis</surname><given-names>LM</given-names></name><name><surname>Gath</surname><given-names>DH</given-names></name><name><surname>Lloyd-Thomas</surname><given-names>AR</given-names></name><name><surname>Tomlinson</surname><given-names>D</given-names></name></person-group><article-title>Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care</article-title><source>BMJ</source><year>1995</year><volume>310</volume><fpage>441</fpage><lpage>445</lpage><pub-id pub-id-type="pmid">7873952</pub-id></citation></ref><ref id="B67"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Willemse</surname><given-names>GR</given-names></name><name><surname>Smit</surname><given-names>F</given-names></name><name><surname>Cuijpers</surname><given-names>P</given-names></name><name><surname>Tiemens</surname><given-names>BG</given-names></name></person-group><article-title>Minimal-contact psychotherapy for sub-threshold depression in primary care. Randomised trial</article-title><source>Br J Psychiatry</source><year>2004</year><volume>185</volume><fpage>416</fpage><lpage>421</lpage><pub-id pub-id-type="pmid">15516551</pub-id><pub-id pub-id-type="doi">10.1192/bjp.185.5.416</pub-id></citation></ref><ref id="B68"><citation citation-type="book"><person-group person-group-type="author"><collab>American Psychiatric Association</collab></person-group><source>DSM-IV-TR</source><year>2000</year><publisher-name>Washington DC: American Psychiatric Association</publisher-name></citation></ref><ref id="B69"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zelman</surname><given-names>DC</given-names></name><name><surname>Brandenburg</surname><given-names>NA</given-names></name><name><surname>Gore</surname><given-names>M</given-names></name></person-group><article-title>Sleep impairment in patients with painful diabetic peripheral neuropathy</article-title><source>Clin J Pain</source><year>2006</year><volume>22</volume><fpage>681</fpage><lpage>685</lpage><pub-id pub-id-type="pmid">16988563</pub-id><pub-id pub-id-type="doi">10.1097/01.ajp.0000210910.49923.09</pub-id></citation></ref><ref id="B70"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Manocchia</surname><given-names>M</given-names></name><name><surname>Keller</surname><given-names>S</given-names></name><name><surname>Ware</surname><given-names>JE</given-names></name></person-group><article-title>Sleep problems, health-related quality of life, work functioning and health care utilization among the chronically ill</article-title><source>Qual Life Res</source><year>2001</year><volume>10</volume><fpage>331</fpage><lpage>345</lpage><pub-id pub-id-type="pmid">11763246</pub-id><pub-id pub-id-type="doi">10.1023/A:1012299519637</pub-id></citation></ref><ref id="B71"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tkachuk</surname><given-names>GA</given-names></name><name><surname>Martin</surname><given-names>GL</given-names></name></person-group><article-title>Exercise Therapy for patients with psychiatric disorders: Research and clinical implications</article-title><source>Professional Psychology: Research and Practice</source><year>1999</year><volume>30</volume><fpage>275</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1037/0735-7028.30.3.275</pub-id></citation></ref><ref id="B72"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blumenthal</surname><given-names>JA</given-names></name><name><surname>Sherwood</surname><given-names>A</given-names></name><name><surname>Babyak</surname><given-names>MA</given-names></name><name><surname>Watkins</surname><given-names>LL</given-names></name><name><surname>Waugh</surname><given-names>R</given-names></name><name><surname>Georgiades</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Effects of exercise and stress management training on markers of cardiovascular risk in patients with ischemic heart disease: a randomized controlled trial</article-title><source>JAMA</source><year>2005</year><volume>293</volume><fpage>1626</fpage><lpage>1634</lpage><pub-id pub-id-type="pmid">15811982</pub-id><pub-id pub-id-type="doi">10.1001/jama.293.13.1626</pub-id></citation></ref><ref id="B73"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dunstan</surname><given-names>DW</given-names></name><name><surname>Daly</surname><given-names>RM</given-names></name><name><surname>Owen</surname><given-names>N</given-names></name><name><surname>Jolley</surname><given-names>D</given-names></name><name><surname>De</surname><given-names>Court</given-names></name><name><surname>Shaw</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>High-intensity resistance training improves glycemic control in older patients with type 2 diabetes</article-title><source>Diabetes Care</source><year>2002</year><volume>25</volume><fpage>1729</fpage><lpage>1736</lpage><pub-id pub-id-type="pmid">12351469</pub-id></citation></ref><ref id="B74"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>BK</given-names></name><name><surname>Saltin</surname><given-names>B</given-names></name></person-group><article-title>Evidence for prescribing exercise as therapy in chronic disease</article-title><source>Scand J Med Sci Sports</source><year>2006</year><volume>16</volume><fpage>3</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">16451303</pub-id><pub-id pub-id-type="doi">10.1111/j.1600-0838.2006.00520.x</pub-id></citation></ref><ref id="B75"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McElroy</surname><given-names>SL</given-names></name><name><surname>Kotwal</surname><given-names>R</given-names></name><name><surname>Malhotra</surname><given-names>S</given-names></name><name><surname>Nelson</surname><given-names>EB</given-names></name><name><surname>Keck</surname><given-names>PE</given-names></name><name><surname>Nemeroff</surname><given-names>CB</given-names></name></person-group><article-title>Are mood disorders and obesity related? A review for the mental health professional</article-title><source>J Clin Psychiatry</source><year>2004</year><volume>65</volume><fpage>634</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">15163249</pub-id></citation></ref><ref id="B76"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>KP</given-names></name><name><surname>Huang</surname><given-names>SY</given-names></name><name><surname>Chiu</surname><given-names>CC</given-names></name><name><surname>Shen</surname><given-names>WW</given-names></name></person-group><article-title>Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial</article-title><source>Eur Neuropsychopharmacol</source><year>2003</year><volume>13</volume><fpage>267</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">12888186</pub-id><pub-id pub-id-type="doi">10.1016/S0924-977X(03)00032-4</pub-id></citation></ref><ref id="B77"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Gura</surname><given-names>KM</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Arsenault</surname><given-names>DA</given-names></name><name><surname>Bistrian</surname><given-names>BR</given-names></name><name><surname>Puder</surname><given-names>M</given-names></name></person-group><article-title>Current clinical applications of omega-6 and omega-3 fatty acids</article-title><source>Nutr Clin Pract</source><year>2006</year><volume>21</volume><fpage>323</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">16870801</pub-id></citation></ref><ref id="B78"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pouwer</surname><given-names>F</given-names></name><name><surname>Nijpels</surname><given-names>G</given-names></name><name><surname>Beekman</surname><given-names>AT</given-names></name><name><surname>Dekker</surname><given-names>JM</given-names></name><name><surname>van Dam</surname><given-names>RM</given-names></name><name><surname>Heine</surname><given-names>RJ</given-names></name><etal></etal></person-group><article-title>Fat food for a bad mood. Could we treat and prevent depression in Type 2 diabetes by means of omega-3 polyunsaturated fatty acids? A review of the evidence</article-title><source>Diabet Med</source><year>2005</year><volume>22</volume><fpage>1465</fpage><lpage>1475</lpage><pub-id pub-id-type="pmid">16241908</pub-id><pub-id pub-id-type="doi">10.1111/j.1464-5491.2005.01661.x</pub-id></citation></ref><ref id="B79"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Dillman</surname><given-names>DA</given-names></name></person-group><source>Mail and Internet Surveys: The Tailored Design Method</source><year>2000</year><edition>2</edition><publisher-name>New York: John Wiley and Sons</publisher-name></citation></ref><ref id="B80"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>LS</given-names></name><name><surname>Jones</surname><given-names>WJ</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Robinson</surname><given-names>RL</given-names></name><name><surname>Weinberger</surname><given-names>M</given-names></name><name><surname>Kroenke</surname><given-names>K</given-names></name></person-group><article-title>Prevalence and impact of depression and pain in neurology outpatients</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2003</year><volume>74</volume><fpage>1587</fpage><lpage>1589</lpage><pub-id pub-id-type="pmid">14617727</pub-id><pub-id pub-id-type="doi">10.1136/jnnp.74.11.1587</pub-id></citation></ref><ref id="B81"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rush</surname><given-names>AJ</given-names></name><name><surname>Gullion</surname><given-names>CM</given-names></name><name><surname>Basco</surname><given-names>MR</given-names></name><name><surname>Jarrett</surname><given-names>RB</given-names></name><name><surname>Trivedi</surname><given-names>MH</given-names></name></person-group><article-title>The Inventory of Depressive Symptomatology (IDS): psychometric properties</article-title><source>Psychol Med</source><year>1996</year><volume>26</volume><fpage>477</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">8733206</pub-id></citation></ref><ref id="B82"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Jonge</surname><given-names>P</given-names></name><name><surname>Bauer</surname><given-names>I</given-names></name><name><surname>Huyse</surname><given-names>FJ</given-names></name><name><surname>Latour</surname><given-names>CH</given-names></name></person-group><article-title>Medical inpatients at risk of extended hospital stay and poor discharge health status: detection with COMPRI and INTERMED</article-title><source>Psychosom Med</source><year>2003</year><volume>65</volume><fpage>534</fpage><lpage>541</lpage><pub-id pub-id-type="pmid">12883102</pub-id><pub-id pub-id-type="doi">10.1097/01.PSY.0000077504.01963.1B</pub-id></citation></ref><ref id="B83"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yates</surname><given-names>WR</given-names></name><name><surname>Mitchell</surname><given-names>J</given-names></name><name><surname>Rush</surname><given-names>AJ</given-names></name><name><surname>Trivedi</surname><given-names>MH</given-names></name><name><surname>Wisniewski</surname><given-names>SR</given-names></name><name><surname>Warden</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Clinical features of depressed outpatients with and without co-occurring general medical conditions in STAR*D</article-title><source>Gen Hosp Psychiatry</source><year>2004</year><volume>26</volume><fpage>421</fpage><lpage>429</lpage><pub-id pub-id-type="pmid">15567207</pub-id><pub-id pub-id-type="doi">10.1016/j.genhosppsych.2004.06.008</pub-id></citation></ref><ref id="B84"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Endicott</surname><given-names>J</given-names></name></person-group><article-title>Measurement of depression in patients with cancer</article-title><source>Cancer</source><year>1984</year><volume>53</volume><fpage>2243</fpage><lpage>2249</lpage><pub-id pub-id-type="pmid">6704912</pub-id></citation></ref><ref id="B85"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ludman</surname><given-names>EJ</given-names></name><name><surname>Katon</surname><given-names>W</given-names></name><name><surname>Russo</surname><given-names>J</given-names></name><name><surname>Von Korff</surname><given-names>M</given-names></name><name><surname>Simon</surname><given-names>G</given-names></name><name><surname>Ciechanowski</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Depression and diabetes symptom burden</article-title><source>Gen Hosp Psychiatry</source><year>2004</year><volume>26</volume><fpage>430</fpage><lpage>436</lpage><pub-id pub-id-type="pmid">15567208</pub-id><pub-id pub-id-type="doi">10.1016/j.genhosppsych.2004.08.010</pub-id></citation></ref><ref id="B86"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lowe</surname><given-names>B</given-names></name><name><surname>Unutzer</surname><given-names>J</given-names></name><name><surname>Callahan</surname><given-names>CM</given-names></name><name><surname>Perkins</surname><given-names>AJ</given-names></name><name><surname>Kroenke</surname><given-names>K</given-names></name></person-group><article-title>Monitoring depression treatment outcomes with the patient health questionnaire-9</article-title><source>Med Care</source><year>2004</year><volume>42</volume><fpage>1194</fpage><lpage>1201</lpage><pub-id pub-id-type="pmid">15550799</pub-id><pub-id pub-id-type="doi">10.1097/00005650-200412000-00006</pub-id></citation></ref><ref id="B87"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Hakkaart-van Roijen</surname><given-names>L</given-names></name></person-group><source>Manual Trimbos/iMTA questionnaire for costs associated with psychiatric illness (in Dutch)</source><year>2002</year><publisher-name>Rotterdam: Institute for Medical Technology Assessment</publisher-name></citation></ref><ref id="B88"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Roijen</surname><given-names>LH</given-names></name><name><surname>van Straten</surname><given-names>A</given-names></name><name><surname>Al</surname><given-names>M</given-names></name><name><surname>Rutten</surname><given-names>F</given-names></name><name><surname>Donker</surname><given-names>M</given-names></name></person-group><article-title>Cost-utility of brief psychological treatment for depression and anxiety</article-title><source>Br J Psychiatry</source><year>2006</year><volume>188</volume><fpage>323</fpage><lpage>329</lpage><pub-id pub-id-type="pmid">16582058</pub-id><pub-id pub-id-type="doi">10.1192/bjp.188.4.323</pub-id></citation></ref><ref id="B89"><citation citation-type="book"><person-group person-group-type="author"><collab>Euroqol group</collab></person-group><source>Eq-5D user guide</source><year>1995</year><publisher-name>Rotterdam: Sanders instituut, EUR</publisher-name></citation></ref><ref id="B90"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>JE</given-names><suffix>Jr</suffix></name><name><surname>Sherbourne</surname><given-names>CD</given-names></name></person-group><article-title>The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection</article-title><source>Med Care</source><year>1992</year><volume>30</volume><fpage>473</fpage><lpage>483</lpage><pub-id pub-id-type="pmid">1593914</pub-id><pub-id pub-id-type="doi">10.1097/00005650-199206000-00002</pub-id></citation></ref><ref id="B91"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lamers</surname><given-names>LM</given-names></name><name><surname>McDonnell</surname><given-names>J</given-names></name><name><surname>Stalmeier</surname><given-names>PF</given-names></name></person-group><article-title>The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies</article-title><source>Health economics</source><year>2006</year><volume>15</volume><fpage>1121</fpage><lpage>1132</lpage><pub-id pub-id-type="pmid">16786549</pub-id><pub-id pub-id-type="doi">10.1002/hec.1124</pub-id></citation></ref><ref id="B92"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lamers</surname><given-names>LM</given-names></name><name><surname>Stalmeier</surname><given-names>PF</given-names></name><name><surname>McDonnell</surname><given-names>J</given-names></name></person-group><article-title>Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff</article-title><source>Ned Tijdschr Geneeskd</source><year>2005</year><volume>149</volume><fpage>1574</fpage><lpage>1578</lpage><pub-id pub-id-type="pmid">16038162</pub-id></citation></ref><ref id="B93"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Hemert</surname><given-names>AM</given-names></name></person-group><source>Lichamelijke Klachten Vragenlijst</source><year>2003</year><publisher-name>Leiden, Leids Universitair Medisch Centrum</publisher-name><comment>Ref Type: Report</comment></citation></ref><ref id="B94"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rief</surname><given-names>W</given-names></name><name><surname>Hiller</surname><given-names>W</given-names></name></person-group><article-title>A new approach to the assessment of the treatment effects of somatoform disorders</article-title><source>Psychosomatics</source><year>2003</year><volume>44</volume><fpage>492</fpage><lpage>498</lpage><pub-id pub-id-type="pmid">14597684</pub-id><pub-id pub-id-type="doi">10.1176/appi.psy.44.6.492</pub-id></citation></ref><ref id="B95"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Speckens</surname><given-names>AE</given-names></name><name><surname>Spinhoven</surname><given-names>P</given-names></name><name><surname>Sloekers</surname><given-names>PP</given-names></name><name><surname>Bolk</surname><given-names>JH</given-names></name><name><surname>van Hemert</surname><given-names>AM</given-names></name></person-group><article-title>A validation study of the Whitely Index, the Illness Attitude Scales, and the Somatosensory Amplification Scale in general medical and general practice patients</article-title><source>J Psychosom Res</source><year>1996</year><volume>40</volume><fpage>95</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">8730649</pub-id><pub-id pub-id-type="doi">10.1016/0022-3999(95)00561-7</pub-id></citation></ref><ref id="B96"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pilowsky</surname><given-names>I</given-names></name></person-group><article-title>Dimensions of hypochondriasis</article-title><source>Br J Psychiatry</source><year>1967</year><volume>113</volume><fpage>89</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">6029373</pub-id></citation></ref><ref id="B97"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smets</surname><given-names>EM</given-names></name><name><surname>Garssen</surname><given-names>B</given-names></name><name><surname>Bonke</surname><given-names>B</given-names></name><name><surname>De Haes</surname><given-names>JC</given-names></name></person-group><article-title>The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue</article-title><source>J Psychosom Res</source><year>1995</year><volume>39</volume><fpage>315</fpage><lpage>325</lpage><pub-id pub-id-type="pmid">7636775</pub-id><pub-id pub-id-type="doi">10.1016/0022-3999(94)00125-O</pub-id></citation></ref><ref id="B98"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>RA</given-names></name></person-group><article-title>Reliability and validity of the Multidimensional Fatigue Inventory (MFI-20) and the Rhoten Fatigue Scale among rural cancer outpatients</article-title><source>Cancer Nurs</source><year>1998</year><volume>21</volume><fpage>370</fpage><lpage>373</lpage><pub-id pub-id-type="pmid">9775488</pub-id><pub-id pub-id-type="doi">10.1097/00002820-199810000-00009</pub-id></citation></ref><ref id="B99"><citation citation-type="book"><person-group person-group-type="author"><collab>WHO</collab></person-group><source>Disability Assessment Schedule II (WHO-DAS-II), brief version pilot, interviewer's manual</source><year>1998</year><publisher-name>Geneva: WHO</publisher-name></citation></ref><ref id="B100"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Van der Linden</surname><given-names>MHM</given-names></name></person-group><source>De verstandhouding tussen cliÃ«nt en therapeut: een empirisch onderzoek naar de kwaliteit van de therapeutische werkrelatie en effect bij psychodynamische psychotherapie (The relationship between therapist and client: an empirical investigation of the quality of the therapeutic relationship and the effect of psychodynamic psychotherapy)</source><year>1994</year></citation></ref><ref id="B101"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luborksy</surname><given-names>L</given-names></name><name><surname>Barber</surname><given-names>JP</given-names></name><name><surname>Siqueland</surname><given-names>L</given-names></name><name><surname>Johnson</surname><given-names>S</given-names></name><name><surname>Najavits</surname><given-names>LM</given-names></name><name><surname>Frank</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>The Revised Helping Alliance Questionnaire (HAq-II). Psychometric Properties</article-title><source>Journal of Psychotherapy Practice and Research</source><year>1996</year><volume>5</volume><fpage>260</fpage><lpage>271</lpage></citation></ref><ref id="B102"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Botega</surname><given-names>N</given-names></name><name><surname>Blizard</surname><given-names>R</given-names></name><name><surname>Wilkinson</surname><given-names>DG</given-names></name><name><surname>Mann</surname><given-names>A</given-names></name></person-group><article-title>General practitioners and depression first use of the depression attitude questionnaire</article-title><source>International Journal of Methods for Psychiatric Research</source><year>1992</year><volume>4</volume><fpage>169</fpage><lpage>180</lpage></citation></ref><ref id="B103"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dowrick</surname><given-names>C</given-names></name><name><surname>Gask</surname><given-names>L</given-names></name><name><surname>Perry</surname><given-names>R</given-names></name><name><surname>Dixon</surname><given-names>C</given-names></name><name><surname>Usherwood</surname><given-names>T</given-names></name></person-group><article-title>Do general practitioners' attitudes towards depression predict their clinical behaviour?</article-title><source>Psychol Med</source><year>2000</year><volume>30</volume><fpage>413</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">10824661</pub-id><pub-id pub-id-type="doi">10.1017/S0033291799001531</pub-id></citation></ref><ref id="B104"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname><given-names>TH</given-names></name><name><surname>Rahe</surname><given-names>RH</given-names></name></person-group><article-title>The Social Readjustment Rating Scale</article-title><source>J Psychosom Res</source><year>1967</year><volume>11</volume><fpage>213</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">6059863</pub-id><pub-id pub-id-type="doi">10.1016/0022-3999(67)90010-4</pub-id></citation></ref><ref id="B105"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Hoekstra</surname><given-names>HA</given-names></name><name><surname>De Fruyt</surname><given-names>F</given-names></name></person-group><source>NEO-PI-R en NEO-FFI: Big Five Persoonlijkheidsvragenlijsten: Handleiding</source><year>1996</year><publisher-name>Lisse: Swets &amp; Zeitlinger</publisher-name></citation></ref><ref id="B106"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Oostenbrink</surname><given-names>JB</given-names></name><name><surname>Bouwmans</surname><given-names>CAM</given-names></name><name><surname>Koopmanschap</surname><given-names>MA</given-names></name><etal></etal></person-group><source>Handleiding voor kostenonderzoek, methoden en standaardkostprijzen voor economische evaluaties in de gezondheidszorg College voor zorgverzekeringen</source><year>2004</year></citation></ref><ref id="B107"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Roijen</surname><given-names>L</given-names></name><name><surname>Essink-Bot</surname><given-names>ML</given-names></name><name><surname>Koopmanschap</surname><given-names>MA</given-names></name><etal></etal></person-group><article-title>Labor and health status in economic evaluation of health care. The Health and Labor Questionnaire</article-title><source>Int J Technol Assess Health Care</source><year>1996</year><volume>12</volume><fpage>405</fpage><lpage>415</lpage><pub-id pub-id-type="pmid">8840661</pub-id></citation></ref><ref id="B108"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Dam</surname><given-names>QD</given-names></name><name><surname>Spijker</surname><given-names>A</given-names></name><name><surname>Arends</surname><given-names>LR</given-names></name><etal></etal></person-group><article-title>Costeffectiveness of psychotherapy: A feasibility study (in Dutch)</article-title><source>Journal of Psychotherapy</source><year>1998</year><volume>24</volume><fpage>5</fpage><lpage>22</lpage></citation></ref><ref id="B109"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koopmanschap</surname><given-names>MA</given-names></name><name><surname>Rutten</surname><given-names>FF</given-names></name></person-group><article-title>A practical guide for calculating indirect costs of disease</article-title><source>Pharmacoeconomics</source><year>1996</year><volume>10</volume><fpage>460</fpage><lpage>466</lpage><pub-id pub-id-type="pmid">10172868</pub-id></citation></ref><ref id="B110"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koopmanschap</surname><given-names>MA</given-names></name><name><surname>Rutten</surname><given-names>FF</given-names></name><name><surname>van Ineveld</surname><given-names>BM</given-names></name><name><surname>van Roijen</surname><given-names>L</given-names></name></person-group><article-title>The friction cost method for measuring indirect costs of disease</article-title><source>J Health Econ</source><year>1995</year><volume>14</volume><fpage>171</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">10154656</pub-id><pub-id pub-id-type="doi">10.1016/0167-6296(94)00044-5</pub-id></citation></ref><ref id="B111"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rubin</surname><given-names>DB</given-names></name></person-group><article-title>Multiple imputation after 18+ years</article-title><source>J Am Stat Assoc</source><year>1996</year><volume>91</volume><fpage>473</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.2307/2291635</pub-id></citation></ref><ref id="B112"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Hout</surname><given-names>BA</given-names></name><name><surname>Al</surname><given-names>MJ</given-names></name><name><surname>Gordon</surname><given-names>GS</given-names></name><name><surname>Rutten</surname><given-names>FF</given-names></name></person-group><article-title>Costs, effects and C/E-ratios alongside a clinical trial</article-title><source>Health Econ</source><year>1994</year><volume>3</volume><fpage>309</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">7827647</pub-id></citation></ref></ref-list></back></article>